|Stewart Abbot||Adicet Bio Inc|
|Johanna Abend||BioMarin Pharmaceutical Inc|
Senior Scientist, Immunogenicity Assessment
Johanna Abend received her Ph.D. in Microbiology and Immunology from the University of Michigan, Ann Arbor in 2008, where the focus of her research was aimed at investigating cytokine-mediated regulation of the human polyomavirus BKV. She continued her training in virus-host interactions with a post-doctoral fellowship at the NCI/NIH in Bethesda, MD where she investigated cellular targets of Kaposi’s sarcoma-associated herpesvirus (KSHV) microRNAs, with a particular interest in immune-related targets (TWEAKR and IRAK1). Following her post-doctoral training, she worked at the Novartis Institutes for BioMedical Research (NIBR) in Emeryville, CA as an investigator and Project Team Leader for multiple antiviral drug discovery teams targeting polyomaviruses and Hepatitis B virus (HBV) using both biologics and small molecule modalities. After seven years at Novartis, Johanna joined BioMarin in January of 2019 as a Senior Scientist in Immunogenicity Assessment where she has supported the filing of a supplemental BLA for Palynziq, a PEGylated enzyme substitution therapy for the treatment of PKU. Johanna has over 8 years of industry experience in antiviral drug development and immunology.
|Marla Abodeely, PhD||Sanofi|
Director, Bioassay, Global MAST Analytical Science and Technology
Marla Abodeely has been working in the Bioassay/Immunoassay field for over 12 years. During this time, she has worked with both small and large biotech companies in all stages of product development, from discovery to post-commercialization. Her primary focus has been protein therapeutics, including enzymes, GPCRs, fusion proteins and antibodies. She is currently the Director of Bioassay within the Global Manufacturing Sciences & Technology (MSAT) group at Sanofi Genzyme located in Framingham, Ma. Previously, she was Associate Director, Head of Bioassay/ Immunoassay (Potency and Process Residuals) within the Analytical Method Development group at Shire Pharmaceuticals (now Takeda). She received her B.S. in Biology at Columbia University in New York, NY with a focus in molecular genetics and earned her Ph.D. in the Biomedical Sciences at the University of California, San Francisco (UCSF) with a focus in biochemistry and cell biology.
|Omar Abudayyeh||Massachusetts Institute of Technology|
No bio available
|Adnan Abu-Yousif||Takeda Pharmaceuticals Inc|
Associate Director IO Biology
Adnan Abu-Yousif leads execution of the targeted payload strategy in discovery at Takeda Oncology. Prior to that, he contributed to the discovery and translational support of Merrimack Pharmaceuticals pipeline molecules. He first explored the biological properties of a variety of targeted delivery vectors including an EGFR+ tumor-targeted, activatable photoimmunoconjugate under the supervision of his postdoctoral mentor, Dr. Tayyaba Hasan and hasn’t looked back. Adnan has a PhD in Pharmacology, Toxicology and Experimental Therapeutics from the University of Kansas.
|Gregory Adams, PhD||Elucida Oncology Inc|
Dr. Adams is Chief Scientific Officer of Elucida Oncology, a clinical stage company developing antibody-toxin fusion proteins for the treatment of cancer. In this role he is responsible for guiding the development of the company’s pipeline assets. Before moving to biotech, Dr. Adams was the Director of Biological Research and Therapeutics and previously co-led the Developmental Therapeutics Program at the Fox Chase Cancer Center, an NCI designated comprehensive cancer center in Philadelphia. Dr. Adams is an immunologist with over 30 years of experience in developing antibody-based agents for the treatment and detection of cancer. He received a Ph.D. in Immunology from the University of California at Davis in 1991. He joined Fox Chase Cancer Center in Philadelphia where he led a laboratory focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer. Dr. Adams serves on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals. He has served on the Scientific Advisory Boards of a number of biotechnology companies including Endo Pharmaceuticals, Symphogen, Avipep, Viventia Bio, AvidBiologics, Xerion, Fabrus, Integral Molecular and YM Biosciences.
|Anirban Adhikari, PhD||Parvus Therapeutics Inc|
Associate Director Biologics Research
Anirban has over 8 years of experience in the biopharmaceutical industry spanning biologic drugs including monoclonal antibodies, novel antibody-based therapeutics and recombinant fusion proteins. Anirban has developed and implemented efficient workflow for recombinant protein production and analytical characterization and applied these technologies for advancing biologics projects for immuno-oncology and protein engineering of immune cell receptors. Anirban has also led a CMC analytical development team and has broad experience in biologics development. Prior to joining Parvus, Anirban held positions of increasing scientific responsibility at Bayer, Pfizer and Elan Pharmaceuticals. Anirban earned his PhD degree in Molecular Biophysics from University of Texas Southwestern Medical Center and pursued his postdoctoral research at UT Southwestern and UCSF medical center.
|Adam Adler, PhD||Universityersity of Connecticut Farmington|
Associate Professor, Immunology
Dr. Adler received his Ph.D. in 1993 from Columbia University where he studied hormonal regulation of gene expression. His post-doctoral research at The Johns Hopkins University School of Medicine focused on studying T cell tolerance pathways, and how they impact tumor immunity. His laboratory at the UConn Health School of Medical currently studies how costimulatory agonists overcome T cell tolerance to tumor antigens, and how this knowledge can be leveraged to boost the efficacy of agonist immunotherapy.
|Prasad Adusumilli||Memorial Sloan Kettering Cancer Center|
Assistant Professor Surgery & Deputy Chief, Thoracic Services
Dr. Prasad Adusumilli is a thoracic surgeon in New York, New York and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Guntur Medical College NTR and has been in practice for more than 20 years.
|Mahiuddin Ahmed, PhD||Y mAbs Therapeutics Inc|
Mahiuddin Ahmed, PhD is the Chief Scientific Officer of Y-mAbs Therapeutics and specializes in bispecific antibody engineering. He received his PhD in Biochemistry and Structural Biology from Stony Brook University and completed postdoctoral training in cancer immunotherapy at the Sloan Kettering Institute. Prior to joining Y-mAbs, Dr. Ahmed was an Assistant Member in the Department of Pediatrics at Memorial Sloan Kettering Cancer Center.
|Yoshiko Akamatsu||AbbVie Inc|
Senior Principal Research Scientist Biologics Discovery
Dr. Yoshiko Akamatsu received Ph.D. in Biophysics from Kyoto University and completed postdoctoral training at Harvard Medical School. She was an Associate Professor in the University of Tokushima, Japan, before she decided to move to the US to work at a biotech company in 2003. Since then, she has been conducting research in the area of antibody and protein engineering in PDL BioPharma, Facet Biotech, Abbott and Abbvie.
|Christopher Alabi||Cornell University|
Assoc Prof, Chemical & Biomolecular Engineering
Christopher Alabi began his research career as an undergraduate researcher in synthetic organic chemistry under the direction of Dr. David Schuster at NYU. Upon receiving his B.S. in Chemistry from NYU and B.E. in Chemical Engineering from Stevens Institute of Technology, he went on to pursue a graduate degree in Materials Chemistry at California Institute of Technology with Dr. Mark Davis. He then moved to MIT in 2009 and served as NIH Postdoctoral Fellow with Dr. Langer and Anderson. Chris Alabi joined the Cornell faculty in 2013 as an Assistant Professor in the School of Chemical and Biomolecular Engineering. He has won several awards during his short tenure at Cornell including the PhRMA Foundation Research Starter Award, NSF CAREER Award, the 2016 Cornell Engineering Research Excellence Award, the 2017 Tau Beta Pi Professor of the Year Award and the 2018 PMSE Young Investigator Award. In 2019, Chris Alabi was promoted to Associate Professor with Indefinite Tenure. Research in the Alabi lab seeks to understand how the composition and sequence of a macromolecular chain affects its chemical, structural and biological properties with an eye towards engineering sustainable materials and biomolecular therapeutics.
|Ramon Alemany, PhD||IDIBELL|
Researcher Cancer Virotherapy, Cancer & Human Molecular Genetics
Ramon Alemany did his PhD in Biology at the University of Barcelona. Since 1993, he held postdoctoral positions at the MD Anderson Cancer Center, Baxter Healthcare, and the University of Alabama at Birmingham. In 2001, he joined the Catalan Institute of Oncology/Institute of Biomedical Research of Bellvitge. He is author of numerous papers on oncolytic adenoviruses, co-founder of VCN Biosciences, and former President of the Spanish Society of Gene and Cell Therapy.
|Amr Ali, PhD||Biogen|
Amr Ali’s research focuses on leveraging multi-omics techniques to improve bioprocesses as well as developing new analytical methods for characterization of complex therapeutic proteins. He has been at Biogen for 9 years and had many roles throughout his tenure there ranging from raw material analysis, cell culture development and protein characterization. Amr Ali has a PhD in analytical chemistry from Northeastern University as well as a master’s degree in bioinformatics and a bachelor’s in biomedical engineering from Boston University.
|Juan Almagro||GlobalBio Inc|
Founder & Director
Dr. Juan C. Almagro is an internationally recognized expert in engineering and development of antibody-based therapeutics. In part with support from the National Science Foundation, he founded GlobalBio to provide collaborative services in the areas of discovery, optimization and development of biotherapeutics. Prior to founding GlobalBio, he was a Senior Director at Pfizer and Research Fellow and Head of Antibody Design at Johnson and Johnson. Before joining the Pharma/Biotech industry, Dr. Almagro was Visiting Scientist at Florida International University, Affiliated Visiting Scientist at Fred Hutchinson Cancer Research Center, Visiting Professor at Simon Fraser University and Associate Professor and Group Leader at The National University of Mexico. He has authored over 70 publications, encompassing more than 50 peer-reviewed scientific articles, 6 book chapters, and 20 international patents. Dr. Almagro serves as reviewer in Immunology and Protein Engineering journals, as well as for grant agencies in several countries. He has participated in the Scientific Advisory Boards of several Biotech companies, has chaired and given talks and lectures at major domestic and international scientific meetings, and has been expert witness in several Intellectual Property litigations between large biopharma organizations.
|Eric Alonzo||bluebird bio|
Senior Scientist, Cell Analytics
Dr. Alonzo currently leads the Immuno-oncology characterization and analytics team in the Process and Analytical Development Department at bluebird bio. His research focuses on development of analytical and characterization assays for the CARs T/TCR cell program. Prior to bluebird bio, Dr. Alonzo led efforts developing T cell-based therapies at Agenus (Lexington, MA), and previous to his work at Agenus, he was a postdoctoral fellow at Massachusetts General Hospital/Harvard Medical School where he worked on a mouse model of T cell acute lymphoblastic leukemia. Dr. Alonzo received his PhD from the Cancer Biology Program at the Memorial Sloan-Kettering Cancer Center.
|Richard Altman||Thermo Fisher Scientific|
Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group
Rich Altman has 30 years of experience in protein expression and production. In early 2019, he joined Thermo Fisher Scientific as a Field Application Scientist. Previously, he worked for several pharmaceutical companies, including Amgen, Alexion, Bayer, and Upjohn, on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the Universityersity of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.
|Richard Altman, MS||Thermo Fisher Scientific|
Field Application Scientist, Life Science Solutions
No bio available
|Nathan Alves||Indiana University School of Medicine|
Asst Prof, Emergency Medicine
Dr. Alves received his PhD in Chemical and Biomolecular Engineering from the University of Notre Dame. The research he conducts, while spanning many disciplines, is centered on the development of translational technologies, treatments, and techniques that can be utilized to have a positive impact on people’s lives. He has extensive experience in: site-specific antibody modification, oriented antibody immobilization for advanced diagnostics, nanoparticle delivery, and packaging of pharmaceutical agents/enzymes to treat various diseases. Currently, Dr. Alves is an Assistant Professor at the Indiana University School of Medicine in the Department of Emergency Medicine with a joint appointment at Purdue in Biomedical Engineering. His multidisciplinary background affords him a unique perspective to tackle complex medical device and therapeutic development problems.
|Zhiqiang An||University of Texas Houston|
Dr. Zhiqiang An is Professor of Molecular Medicine, the Robert A. Welch Distinguished University Chair in Chemistry, and Director of the Texas Therapeutics Institute at the University of Texas Health Science Center at Houston. His laboratory focuses on cancer antibody drug resistance mechanisms, biomarkers for cancer therapeutic antibodies, and antibody drug discovery targeting cancer and infectious diseases. Dr. An also directs the Therapeutic Monoclonal Antibody Lead Optimization and Development Core Facility funded by the Cancer Prevention and Research Institute of Texas (CPRIT). Previously, he served as Chief Scientific Officer at Epitomics, Inc. and was Director of Biologics Research at Merck Research Laboratories. He started his biotech career at Millennium Pharmaceuticals. Dr. An received his Ph.D. degree from the University of Kentucky and his postdoctoral training at the University of Wisconsin-Madison. He is an elected fellow of Society for Industrial Microbiology and Biotechnology. He is also an elected fellow of the American Academy of Microbiology.
|Denise Aronson||Safety Partners, Inc.|
Founder and CEO
Denise is a pioneer in the life science EHS industry. Denise founded Safety Partners Inc. in 1992. Since then, Denise and her team have implemented safety programs for more than 550 of the top life science companies in the northeast. Prior to founding Safety Partners, Denise served as an EHS manager at T Cell Sciences and managed a clinical prenatal diagnostics laboratory.
She began her career as a research associate at Beth Israel Deaconess Hospital in Boston, after receiving a BS in Biochemistry from the University of New Hampshire. Denise is a certified chemical hygiene officer through the National Registry of Certified Chemists.
She is active in many professional societies and trade organizations and was a founding member of several leads groups in MA and NYC. Denise is a regular on the industry speaking circuit, a member of the MassBio SEF Working Group, and an American Chemical Society (ACS) Expert. Safety Partners is a Certified Woman-Owned Business and has been named one of the 25 Best Small Companies by Working Mother magazine.
|Tara Arvedson, PhD||Amgen|
Director, Oncology Research
Tara Arvedson, Executive Director in Oncology Research at Amgen, has led multiple T cell therapeutic programs and is currently responsible for a large portfolio of T cell therapeutic assets and platform strategy. She received her Ph.D. at Caltech and was later a Damon Runyon Cancer Research Fellow at UC San Diego.
|Marc Bailly||Merck Research Labs|
Associate Principal Scientist
Marc Bailly obtained his PhD in Biochemistry from University Louis Pasteur in Strasbourg, France in Pr. Daniel Kern’s team. After two postdocs in bioinformatics and human T cell development, Marc joined Merck in 2015 where he focused on high throughput analytical characterization technologies enabling lead candidate selection for biologics programs. Marc also worked at MacroGenics focusing on the DART bispecific platforms. Currently Marc is co-leading the analytical characterization group at Merck South San Francisco site. He is focusing on analytical characterization and high throughput data management using bioassays to facilitate the development of machine learning algorithms aiming at predicting developability profiles of antibodies and other biologics modalities.
|Robyn Barfield, PhD||Catalent|
Group Leader, Chemical Biology
No bio available
|Alexey Berezhnoy, PhD||MacroGenics Inc|
Alexey Berezhnoy is a scientist in the Cell Biology and Immunology group at MacroGenics, Inc., which he joined in 2016 from a faculty position in the Department of Medicine University of Miami. Dr. Berezhnoy has been active in tumor immunology research for the past 10+ years, focusing on novel therapeutic approaches, including multi-specific molecules and tumor-targeted therapies. Dr. Berezhnoy has authored several high-impact publications in the field of immuno-oncology.
|Imre Berger, PhD||University Of Bristol|
Imre Berger was trained at Leibniz University Hannover (Germany), MIT (USA) and ETH Zurich (Switzerland), Imre held faculty positions at ETH and EMBL before joining University of Bristol, UK in 2014. AT Bristol, he is Professor and Chair in Biochemistry and Chemistry, Director of the Bristol synthetic biology research centre BrisSynBio and Co-Director of the Bristol biodesign institute BBI. Imre published more than 100 papers in leading journals, co-founded three biotech companies and won several distinctions including the Swiss Technology Award, the Swiss Venture Award (2nd prize), the DeVigier Foundation Award and a Wellcome Trust Senior Investigator Award for his innovative research. Since 2019, Imre Berger is Investigator of the European Research Council (ERC) and Founding Director of the Max Planck Bristol Centre for Minimal Biology.
|Goncalo Bernardes||University of Cambridge|
Reader (Assoc Prof), Chemical Biology
After completing his D.Phil. in 2008 at the University of Oxford, U.K., he undertook postdoctoral work at the Max-Planck Institute of Colloids and Interfaces, Germany, and the ETH Zürich, Switzerland, and worked as a Group Leader at Alfama Lda in Portugal. He started his independent research career in 2013 at the University of Cambridge as a Royal Society University Research Fellow. In 2018 he was appointed University Lecturer (Tenured) and recently has been promoted to Reader (Associate Professor). Gonçalo is the recipient of two European Research Council grants; a starting grant and a proof-of-concept grant, and was awarded the Harrison–Meldola Memorial Prize in 2016 and the MedChemComm Emerging Investigator Lectureship in 2018, both from the Royal Society of Chemistry. His research group interests focus on the use of chemistry principles to tackle challenging biological problems for understanding and fight cancer.
|Chantale Bernatchez||MD Anderson Cancer Center|
Assistant Professor, Melanoma Medical Oncology Research
No bio available
|Allison Betof Warner||Memorial Sloan Kettering Cancer Center|
Allison Betof Warner, MD, PhD is an Assistant Attending Physician on the Melanoma Service and Early Drug Development Service at Memorial Sloan Kettering Cancer Center. Dr. Betof graduated magna cum laude from Cornell University and went on to graduate with her MD/PhD from the Medical Scientist Training Program at Duke University. She completed her PhD under the supervision of Drs. Mark Dewhirst and Lee Jones, studying the effects of exercise on tumor angiogenesis and chemotherapeutic efficacy. Dr. Betof went on to Internal Medicine residency at Massachusetts General Hospital then Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center, where she joined the faculty in July 2019. Her research explores how pharmacologic and non-pharmacologic modulations in tumor microenvironment affect tumor immunobiology and immunotherapy.
|Nicoletta Bivi||Eli Lilly & Co|
Director, Experimental Medicine La
Nicoletta Bivi received her Master’s degree in Biotechnology from the University of Trieste in 2003 and subsequently completed a PhD in Molecular Biology from the University of Udine in 2008. Dr. Bivi joined Eli Lilly and Company in 2012 from Indiana University School of Medicine, where she was an Assistant Professor.
In her current role as the Director of Assay Development, Dr Bivi leads a team of scientists who develop novel biomarker, target engagement, and immunogenicity assays to support all therapeutic areas and phases of Eli Lilly and Company’s portfolio. In addition, Dr Bivi’s laboratory contributes to the assessment of pre-clinical immunogenicity risk.
Dr. Bivi’s interests include immunoassays and mechanisms of immunogenicity. Recently, her laboratory was the first to demonstrate that pre-existing reactivity assessment of biotherapeutics can predict clinical immunogenicity and the epitope(s) targeted by the anti-drug antibodies.
Dr. Bivi is the author or co-author of more than 20 peer-reviewed scientific papers.
|Alexis Bloom||Gyroscope Therapeutics|
Vice President Regulatory Affairs
Alex Bloom serves as VP Regulatory Affairs and Quality Assurance at Gyroscope Therapeutics, a UK-headquartered company focused on developing products and surgical delivery devices to preserve sight and fight the devastating impact of blindness. Gyroscope’s leads investigational gene therapy, GT005, is in development to treat the leading cause of blindness, dry age-related macular degeneration (dry AMD). Prior to Gyroscope, Alex has spent the past decade working on the development and regulation of cell and gene therapies. He has worked on over 40 ATMP programs, including as the regulatory lead for Holoclar®, the first stem cell-based medicine to receive approval in the West. Prior to working in Regulatory Affairs, Alex spent time in manufacturing and process development positions for recombinant protein products. He received his PhD from the University of Sheffield (UK).
|Bjoern Boll||Novartis Pharma AG|
Principal Scientist & Head, Particle Lab
Dr. Boll studied in Göttingen and received his PhD from the University of Tübingen in Germany focusing on purification and characterization of proteins of antibiotic biosynthesis. He afterwards performed studies of the biological consequences of sub-visible particles at the Analytical Development Department at Roche in Basel, Switzerland. After joining Merrimack Pharmaceuticals in the Boston area and driving the physical-chemical characterization of early phase projects, Dr. Boll is now heading the particle lab and higher order structure analytics at Novartis in Basel, Switzerland.
|Ezio Bonvini, MD||MacroGenics Inc|
CSO & Senior Vice President Research
Ezio Bonvini joined MacroGenics in 2003 after a career at the National Cancer Institute, NIH, and the Center for Biologics Evaluation and Research, FDA, where he last served as the Chief of the Laboratory of Immunobiology and the Acting Deputy Director of the Division of Monoclonal Antibodies. A physician by training, Dr. Bonvini is an expert in immunobiology and drug development, has authored numerous publications in the field of signal transduction, immunology and immune-oncology, and is an inventor on several patents.
|Gadi Bornstein, PhD||TESARO|
Senior Director Biologics Discovery
Dr. Bornstein has twenty years of experience in Oncology R&D with an emphasis in preclinical antibody discovery and development. Dr. Bornstein currently leads biologics discovery efforts at TESARO, a GSK company. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the University of Southern California Keck School of Medicine. Dr. Bornstein completed his postdoctoral training at Stanford University in the Division of Immunology and Rheumatology.
Following his postdoctoral training, Dr. Bornstein joined Amgen Fremont, Inc. (formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology department. Dr. Bornstein has held roles of increasing responsibility at AstraZeneca, Pfizer, and Novartis, where he was a project team leader, lead biologist, and key contributor to scientific strategies for multiple oncology programs.
|Adrian Bot, MD, PhD||Kite Pharma Inc|
Vice President Translational Medicine
Adrian Bot, M.D., PhD is the Vice President of Translational Sciences at Kite, a Gilead Company. Kite is a biotechnology company developing genetically engineered T cell therapies, based in Los Angeles, CA. He has more than 20 years of experience in biomedical research and development. Dr. Bot obtained his M.D. at the University of Medicine and Pharmacy in Timisoara – Romania and his PhD in Biomedical Sciences at Mount Sinai School of Medicine in New York. Subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla and Scientist, Principal Scientist and Director of Immunology Research at Alliance Pharmaceutical Corp. in San Diego. In Nov 2002, Dr. Bot joined Allecure Pharmaceuticals which became MannKind Corp, where he was a Director of Research and Development. He had several other appointments at MannKind: Sr. Director of Translational Medicine, Vice President of Scientific Management and Vice President of Research, prior to the appointment first as Chief Scientific Officer and then Vice President of Translational Sciences at Kite.
Scientist, Analytical Developmentelopment
George has a BS in chemistry and a PhD in Biochemistry. His graduate studies under Prof. Alan Marshall at Florida State University focused on development and optimization of hydrogen/deuterium exchange mass spectrometry to study protein-protein interactions. Shortly after he graduated, he joined the technical development group at Biogen in 2011 where his job responsibilities focus on the biophysical characterization of proteins and gene therapy products.
|Carlo Boutton||Ablynx a Sanofi Co|
Head, Nanobody Explorative Technologies
Carlo Boutton obtained his PhD in 1999 at the University of Leuven (Belgium) on a subject that investigated the physico-chemical behavior of proteins under high-electromagnetic (laser) fields. After his PhD he joined Algonomics (currently Lonza) where he contributed to the development of EpiBase: a platform to predict and identify T-cell epitopes in biologics. In 2003 he joined Tibotec (subsidiary of Johnson & Johnson) where he was involved in several anti-HIV and anti-HCV projects. He joined Ablynx in 2007 where he focused on improvements of the Nanobody platform and new therapeutic applications for Nanobodies, including bispecifics, immunotherapeutics and ADCs. After the acquisition of Ablynx by Sanofi he holds the position of Head Nanobody Explorative Technologies. Together with his team he is working on a next generation Nanobody platform.
|Ramakrishna Boyanapalli, PhD||WAVE Life Sciences USA Inc|
Rama has a PhD in Biology from Bowling Green State University, Bowling Green, Ohio and Postdoctoral fellowship in immunology and Biochemistry, University of Colorado, Boulder, Colorado. Currently working in department of Bioanalytical and Biomarker Development at Wave Life Sciences, Rama leads a group assessing immunogenicity of oligonucleotides. Before joining Wave, Rama worked for three years at Shire Pharmaceuticals, Lexington, Massachusetts, seven years at Nivalis Therapeutics, and three additional years at RoMonics and Boulder Diagnostics, Boulder, Colorado. He held various positions of increasing responsibilities working on immunogenicity, immunogenicity impact assessment, PK and PD assay development.
|Andrew Bradbury, MB BS, PhD||Specifica Inc|
Andrew Bradbury is one of the founders of Specifica, a member of the Board of Directors, and serves as the Chief Scientific Officer. Andrew has almost 30 years of experience in the field of recombinant antibodies and display technologies. Throughout his career, he has developed and employed novel technologies, including the use of lox recombination to dramatically increase antibody library diversity. Andrew is a vocal proponent for the use of sequenced recombinant antibodies in research to improve reproducibility. He has frequently served as an expert witness in antibody patent cases involving some of the world’s bestselling antibody drugs. Andrew has published over 130 peer-reviewed papers and is the inventor on numerous patents and patent applications. Andrew holds a PhD from Cambridge University, where he studied under Nobel Laureate Cesar Milstein, the inventor of monoclonal antibodies, and holds an MB BS (medical degree) from the University of London as well as a BA and MA from Oxford University.
|Arnd Bradenburg, PhD||Genedata|
Head, Professional Services, Genedata Expressionist
Arnd Brandenburg joined Genedata in 2005 and is heading the Professional Services team of the Expressionist business unit. Before joining Genedata, Arnd worked as a theoretical physicist at DESY, Hamburg, doing research in particle physics and cosmology. He did his PhD in physics at the university of Heidelberg and is a lecturer for bioinformatics and systems biology at the university of Freiburg.
|David Bramhill, PhD||Individual Consultant|
Dr. Bramhill has over 20 years’ experience in biologics, both in large biopharma and startup biotech companies. He has expertise in isolating and improving antibodies using phage display and other display systems and is an inventor on library design for small scaffolds and bi-specific formats. He also has experience in diverse expression systems for producing antibodies, antibody fragments and scaffolds. He has taught numerous technical courses for over 15 years at international conferences and served as a Key Opinion Leader for major BioPharma companies.
|Nick Brown, MSc||Retrogenix Ltd|
North American Business Development Manager
Nick is responsible for growing Retrogenix’s North American business portfolio and is based at our UK headquarters in the Peak District. Prior to Retrogenix, Nick worked in the Centre for Stem Cell Biology at the University of Sheffield, culturing and genetically characterising human pluripotent stem cells. He also spent 4+ years at an engineering firm specialising in ultra-high-performance industrial mixers.
|Elizabeth Brunk, PhD||University of California San Diego|
I am an experienced computational scientist with a focus on developing and applying workflows that integrate large-scale data sets, network-based analysis, and structure-based modeling approaches. I received my doctorate in Chemistry and Chemical Engineering from the Swiss Federal Institute of Technology Lausanne (EPFL), and my post-doc was at UC San Diego Medical School.
|Ingmar Bruns, MD, PhD||Pieris Pharmaceuticals Inc|
Senior Vice President & Head, Clinical Development
Ingmar is Vice President of Clinical Development of the Company. Prior to joining Pieris, from 2013 through October 2017, Dr. Bruns led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Before his tenure at Bayer, Dr. Bruns served as an attending hematologist and oncologist as well as a basic, translational and clinical researcher at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Dr. Bruns has authored over 50 papers in the field of hematology and oncology. He received his M.D. and Ph.D. from the University of Lubeck in Germany.
|Donald Buchsbaum, PhD||University of Alabama Birmingham|
Professor & Director, Radiation Oncology
Donald J. Buchsbaum is a Professor of Radiation Oncology, Surgery, Pathology, Pharmacology & Toxicology, Biomedical Engineering, and Biochemistry & Molecular Genetics at the University of Alabama at Birmingham School of Medicine and plays a leading role in the breast and pancreatic cancer translational research programs that focus on the clinical development of therapeutic agents. These include monoclonal antibodies against epidermal growth factor receptor and TRAIL death receptor 5, small molecule Wnt/ß-catenin inhibitors, plus genomic analysis and precision medicine. Combinatorial studies are investigated with chemotherapy and radiation therapy. In addition, he is investigating therapeutic agents against breast and pancreatic cancer stem cells and immune-based therapies. He is the Co-Leader of the Inflammation, Immunology, and Immunotherapeutics Program in the University of Alabama at Birmingham O'Neal Comprehensive Cancer Center.
|Richard Buick, PhD||Fusion Antibodies plc|
Richard Buick has more than 20 years’ experience in the biopharmaceutical industry and has a PhD in Immunology from Queen’s University Belfast. He joined Fusion Antibodies as a Director and was appointed CTO in 2011, managing all scientific projects and patent portfolios. Fusion Antibodies was admitted to the London Stock Exchange in 2017 and Richard has been expanding the company’s service areas including affinity maturation by in silico design and antibody discovery by B-cell cloning.
|Soren Buus, PhD||University of Copenhagen|
Professor, Department of Immunology and Microbiology
MD PhD, Professor of Immunology, University of Copenhagen. Research interest include: immunogenicity, CD8 and CD4 T cell epitopes and responses, peptide-MHC class I and II interactions (including recombinant MHC class I and II molecules, peptide-MHC I and II binding assays, large-scale data generation, neural network predictors (e.g. NetMHC).
Founder of immunAware, provider of high-quality MHC services and reagents including easYmers (do-it-yourself peptide-MHC tetramers).
|Iain Campuzano||Amgen Inc|
Principal Scientist, Discovery Attribute Sciences
Iain Campuzano works in and manages a core analytical research group within Amgen Research. He has invented/co-invented six mass spectrometry related patents and published over 50 peer reviewed articles and book chapters. He has also presented and organised/chaired sessions at multiple international conferences such as ASMS, ASMS Sanibel, PEGS, Discovery on Target and PITTCON.
|Phillip D. Carter||Orchard Therapeutics|
Head, U.S. Market Access
Phillip D. Carter, Head of U.S. Market Access at Orchard Therapeutics, leads the U.S. team responsible for aligning the needs of payers, patients, and other stakeholders to help ensure Orchard’s potentially curative ex vivo autologous hematopoietic stem cell (HSC) gene therapies can be accessed by those who need them. Driven by a personal passion for improving the lives of patients, Mr. Carter has dedicated more than 20 years of his career to bringing innovative medicines to market, including multiple therapies for rare and ultra-rare conditions. Mr. Carter serves as a collaborative partner and committee member to multiple organizations – including the Financing & Reimbursement of Cures in the U.S. (FoCUS) Project for MIT’s New Drug Development Paradigms (NEWDIGS) program, as well as the Policy, Access and Reimbursement Committee (PARC) at Biotechnology Innovation Organization (BIO).
|Paul Carter, PhD||Genentech Inc|
Senior Staff Scientist & Senior Director Antibody Engineering
Paul Carter is a Senior Director and Staff Scientist in the Antibody Engineering Department at Genentech, Inc. His research interests focus on creating new antibody technologies and applying them to develop future generations of antibody therapeutics. His accomplishments in drug development include initiating the antibody humanization program at Genentech. He is a co-inventor of 5 antibodies that have entered clinical development including one that later became a commercial product (Herceptin). He is a co-inventor of “knobs-into-holes” technology used to create a one-armed antibody and at least 4 bispecific antibodies that have entered clinical development. He also invented technology for high-level antibody fragment expression in E. coli including a Fab fragment that subsequently became a commercial product (Lucentis). He is an inventor or co-inventor on at least 43 issued US patents. He has published more than 100 scientific publications that together have been cited >15,500 times. He received a BA in Natural Sciences from Cambridge University and his Ph. under Sir Gregory Winter, PhD and FRS at the MRC Laboratory of Molecular Biology in Cambridge. He was a Postdoctoral Fellow with Dr. James A. Wells at Genentech. He has over 30 years of experience in biotechnology including Genentech (1986-2000 and 2010-present), Immunex/Amgen (2000-2003), Seattle Genetics (2003-2008) and VLST (2008-2009). His professional experience also includes heading the postdoctoral programs at Genentech, Immunex and Amgen.
During the past 19 years, I have worked on protein engineering and protein production at the Novartis Institutes for BioMedical Research. What motivates me is applying science and creativity to design proteins with desired properties. I got my first degree from the POLYTECH school of Engineering in Marseille. Attracted by the concepts of protein evolution, I joined Pr. Andreas Pluecthun group at the University of Zurich for one-year postgraduate. I started to apply these principles of molecular evolution at Novartis for production of tool proteins used for structural analysis. Finally, I moved to our Biologic Center and could focus on the engineering of therapeutic proteins. I was first involved in the optimization of mAb for better activity and developability before to concentrate on multispecific modalities. Over past year, I contributed to the development of a technology platform that enables efficient discovery, engineering and production of several bispecific formats.
|Jennifer Chadwich, PhD||BioAnalytix, Inc.|
Vice President, Biologic Development
Dr. Jennifer Chadwick is an innovative leader with >15 years professional academic and industrial experience in biotechnology, pharmaceutics and life sciences. She is Vice President of Biologic Development at BioAnalytix and formerly tenured Professor and Louise Byrd Graduate Educator in the Department of Pharmaceutical Chemistry at the University of Kansas. Prof. Chadwick transitioned to industry after founding a company to commercialize technology developed in her academic lab and serving as CSO and Director. She is a recognized expert in analytical development, formulation and stability assessment of biologics and has extensive background in biologic drug discovery, translational research and early/late stage development of complex, emerging therapeutics applied to diverse clinical indications. Her corporate responsibilities have included corporate/scientific enterprise strategy, product development, business development, project management, team building and alliance management, IP portfolio management and early-stage fundraising. Dr. Chadwick has a significant history and ongoing commitment of influential leadership in professional communities and strong engagement in mentoring and career development. She serves as Associate Director, CASSS; Visiting Scholar, Department of Chemistry and Chemical Biology, Northeastern University; Editorial Advisory Board member, Journal of Pharmaceutical Sciences and Scientific Reports; MassBio Steering Committee for Academic-Industry Relations; Mentor for MassCONNECT; and Co-chair of Mentors, Advisors, Peers and Sponsorship, WIB, Boston Chapter.
|Jeiwook Chae, PhD||LegoChem Biosciences|
Chief Business Development Office
Since earning his Ph.D. from University of Virginia, Dr. Jeiwook (Jei) Chae has conducted research both in academic and industry settings, gaining invaluable experience in many aspects of discovery research, animal models for human diseases, and preclinical therapeutic testing. His postdoctoral research at Harvard University was primarily focused on elucidating the mechanism underlying spreading RNAi signals between cells, especially related to cancer biology. His collaborative preclinical research with a leading RNAi therapeutics company, Alnylam, provided important insights for the clinical development of RNAi therapeutics. Subsequently, he joined Bioneer, where he served as Director of Research and conducted preclinical evaluations of a siRNA-based drug technology as well as research into RNAi pipelines involving multiple diseases. As Chief Business Development Officer and VP of Biology at LegoChem Biosciences Dr. Chae currently leads company’s scientific endeavors and has guided academic and industry collaborations, advancing clinical development of pipeline programs including antibiotics, anti-fibrosis, and Antibody-Drug Conjugates (ADC)-based cancer drugs. He has successfully executed transactions with Takeda/Millennium ($404M+ licensing and collaboration agreement for multi-target antibody-drug conjugate, Mar 2019) and Fosun Pharma (licensing agreement for HER2-targeted ADC, Aug 2015).The primary mission of Dr. Jei Chae and his colleagues in LegoChem Biosciences is to develop a clinically validated ADC drugs using ADC platform technology developed by the company including novel site-specific conjugation and proprietary cancer-selectively activated linker and payload.
|Ross Chambers, PhD||Integral Molecular Inc|
Vice President, Antibody Discovery
Ross Chambers is Vice President of Antibody Discovery at Integral Molecular. He pioneered the use of DNA immunization for antibody production and developed Integral Molecular’s B-cell cloning system for antibody isolation. Before joining Integral Molecular, Dr. Chambers was Director of R&D at SDIX, where he directed the discovery of thousands of commercial antibodies.
|John Champagne||Wyatt Technology|
Northeast Regional Manager, Senior Applications Scientist
John Champagne is a Senior Applications Scientist and Regional Manager for Wyatt Technology, responsible for supporting the Northeast US and the Wyatt Applications Lab outside of Boston. He received his M.Sc. and Ph.D. at the University of New Hampshire under the advisory of Professor Thomas Laue where his work focused on the gelation properties of β-Lactoglobulin and the origins of opalescence in self-associating IgG antibodies solutions. Since joining Wyatt in 2002, John has provided a range of analytical support.
Principal Scientist, Global Mfg Science & Technology
Dr. Christine Chan is a protein biochemist with broad experience in the biopharmaceutical industry, including prior experience at Sandoz Pharmaceuticals and Merck & Co., Inc. She specializes in the analysis of recombinant products produced from mammalian cells for vaccines and biologics development. Her application experience includes expression cell line selection, drug substance & drug product process development, manufacturing tech transfers and lifecycle management of commercialized products. Dr. Chan received her Ph.D. from the University of California-Davis and conducted post-doctoral work at the University of Washington. She has authored over 30 publications with two recent reviews on forced degradation studies on protein-based therapeutics and stability testing considerations.
|Javier Chaparro-Riggers, PhD||Pfizer Inc|
Javier worked for 8 years in the field of enzyme engineering and received his PhD in 2003. After his postdoctoral training he joint Pfizer, where he is leading the BioTherapeutic Discovery department within Biomedicine Design. In this role, he is responsible for leading biotherapeutic discovery work, including lead generation and optimization, structural based design, biophysical characterization, and non-GLP biotherapeutic production. Javier is interested in understanding the underlying biology of drug design and delivery and engineering solutions for challenges associated with developing the next generation of biotherapeutics.
|Sidi Chen||Yale University|
Assistant Professor, Genetics
Sidi Chen joined the Yale Faculty in 2015 as an assistant professor in the Department of Genetics and Systems Biology Institute, also as a member of the Yale Cancer Center and the Yale Stem Cell Center. Chen earned a PhD in evolutionary genetics from The University of Chicago with an award-winning dissertation with Dr. Manyuan Long. After graduation he performed postdoctoral studies at MIT under the mentorship of Dr. Phil Sharp, and also the Broad Institute working with Dr. Feng Zhang. His research focuses on providing a global understanding of biological systems. Chen developed and applied genome editing and high-throughput screening technologies, precision CRISPR-based in vivo models of cancer, global mapping of functional drivers of cancer oncogenesis and metastasis. More recently, he developed novel systems that enable rapid identification of novel immunotherapy targets and new modalities of cancer immunotherapy. Dr. Chen received a number of national and international awards including the NIH Director’s New Innovator Award, DoD Era of Hope Scholar Award, Damon Runyon Cancer Research Fellow, Dale Frey Award for Breakthrough Scientists, AACR NextGen Award for Transformative Cancer Research, TMKF Innovative/Translation Cancer Research Award, BCA Exceptional Research Grant Award, MRA Young Investigator Award, V Scholar, Bohmfalk Scholar, Ludwig Family Foundation Award, St. Baldrick’s Foundation Award, CRI Clinic & Laboratory Integration Program (CLIP), MIT TechReview Regional 35 Innovators, Yale-Blavatnik Innovator Award, and Sontag Foundation Distinguished Scientist Award.
|Linzhi Chen, PhD||Boehringer Ingelheim Pharmaceuticals Inc|
Senior Research Fellow & Group Leader
Dr. Chen obtained his PhD degree in organic chemistry from the University of Mons, Belgium. After postdoctoral training, he joined 3M Pharmaceuticals and then Boehringer Ingelheim Pharmaceuticals and has worked primarily on metabolite profiling/ID and bioanalysis in support of small molecule drug development. In recent years at Boehringer Ingelheim, he has led a group to provide LC/MS-based bioanalytical support to biotherapeutic development programs, and developed a number of LC/MS assays for quantitation of various biotherapeutic proteins such as nanobodies, Fabs, bispecifics, mAbs, etc. His group also developed immunocapture-LC/MS methodology for simultaneous ADA isotyping and semi-quantitation. His recent research focuses on LC/MS determination of in vivo biomodifications of biotherapeutics and their impact on PK/PD. Dr. Chen has more than 30 publications in peer-reviewed journals.
|William Chen, PhD||Massachusetts Institute of Technology|
Dr. Chen is a surgeon, engineer, and multidisciplinary scientist with a career vision to improve human health. Dr. Chen is currently a research scientist at Massachusetts Institute of Technology (MIT). He received his M.D. degree and medical training (internship and surgical residency) in Taiwan before pursuing an academic path. Dr. Chen obtained his master’s degree in Biotechnology at the University of Pennsylvania and Ph.D. degree in Bioengineering at the University of Pittsburgh. He finished his first postdoctoral fellowship in Biomaterial and Regenerative Medicine at the University of Pittsburgh. Dr. Chen recently finished his NIH-sponsored joint postdoctoral fellowship at MIT and Massachusetts General Hospital (MGH) under the co-mentorship of Dr. Timothy Lu (MIT) and Dr. Anthony Rosenzweig (MGH). Dr. Chen’s research is focusing on the development of platform technologies for precision biomanufacturing and cardiovascular translational medicine using genetic engineering and synthetic/systems biology approaches.
|Win Cheung||REGENXBIO Inc|
Associate Director, Analytical Development
Win Cheung is Associate Director of the Cell-Based Potency group in the Analytical Development department at REGENXBIO. Prior to joining REGENXBIO, Win was a Senior Manager in Analytical Development at Novavax. Win received his bachelor’s degree in Biochemistry from Worcester Polytechnic Institute and his PhD in Biological Chemistry from The Johns Hopkins University School of Medicine.
|Tony Christopeit||Roche Diagnostics GmbH|
Research Scientist, Pharma Research & Early Developmentelopment
Dr. Tony Christopeit is Research Scientist at Roche Pharma Research & Early Development at the Roche Innovation Center Munich, Germany. He holds a PhD in Biochemistry from the Uppsala University, Sweden. After a postdoctoral training at The Arctic University of Norway in Tromsø, he joined Roche in 2017. The focus of his work is on the functional and biophysical characterization of therapeutic antibodies.
|George Church, PhD||Harvard Medical School|
Robert Winthrop Professor, Genetics
George M. Church, PhD ’84, is professor of genetics at Harvard Medical School, a founding member of the Wyss Institute, and director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications – including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. Church is director of IARPA & NIH BRAIN Projects and National Institutes of Health Center for Excellence in Genomic Science. He has coauthored 450 papers, 105 patents, and one book, “Regenesis”. His honors include Franklin Bower Laureate for Achievement in Science, the Time 100, and election to the National Academies of Sciences and Engineering.
|Jennifer Cochran, PhD||Stanford University|
Shriram Chair & Professor, Bioengineering & Chemical Engineering
Jennifer Cochran is the Shriram Chair of the Department of Bioengineering at Stanford University. She is a Professor of Bioengineering and, by courtesy, Chemical Engineering and a member of the Cancer Biology, Biophysics, and Immunology graduate programs. Dr. Cochran serves as the Director of the Stanford/NIH Biotechnology pre-doctoral training program, and co-Director of the Stanford NIST pre-doctoral training program. Her research group uses interdisciplinary approaches in chemistry, engineering, and biophysics to study complex biological systems and to develop new tools for basic science and biomedical applications. Dr. Cochran translational interests span protein-based drug discovery and development for applications in oncology and regenerative medicine, and development of new technologies for high-throughput protein analysis and engineering. Dr. Cochran obtained her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, where she also completed a postdoctoral fellowship in Biological Engineering.
|Sivan Cohen||Genentech Inc|
Scientist, Cell Biology
No bio available
|Adam Cohen, MD||University of Pennsylvania|
Assistant Professor Hematology & Oncology, Center for Advanced Medicine
Dr. Adam Cohen received his medical degree and did his internal medicine residency at the University of Pennsylvania, Philadelphia. He completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center, New York, including research training in the Laboratory of Tumor Immunology under Alan Houghton, MD. He then served as faculty on the Hematology Service at Fox Chase Cancer Center, Philadelphia. Currently, he is Director of Myeloma Immunotherapy, and an Assistant Professor of Medicine at the Abramson Cancer Center, University of Pennsylvania, Philadelphia. Dr. Cohen is board certified in medical oncology and hematology. He is a member of ASCO, ASH, and AACR. He is also a member of the Multiple Myeloma Committee, Eastern Cooperative Oncology Group, and has served on the NCCN Multiple Myeloma Guidelines Panel. He is a medical advisor for the Myeloma Beacon, and an ad hoc reviewer for Leukemia, Blood, and Clinical Cancer Research, among other journals. His research interests involve novel therapeutics for plasma cell diseases, particularly vaccines and cellular immunotherapies. He has co-authored over 50 original articles, chapters, and reviews on cancer vaccines, tumor immunity, multiple myeloma, amyloidosis, and stem cell transplant.
|Matthew Coleman, PhD||Lawrence Livermore Natl Lab|
Senior Scientist & Group Leader
Dr. Coleman is a senior biomedical staff scientist at Lawrence Livermore National Laboratory and an adjunct professor in the department of Radiation Oncology at University of California Davis School of Medicine and. He received his Ph.D. in molecular biochemistry and cellular biology from Boston University. Dr. Coleman has authored over 150 publications in peer-reviewed journals, published proceedings and book chapters covering a diverse breadth of molecular biology and biochemistry. He has over 19 years of experience in developing biotechnology and characterizing genomic responses of genotoxic stressors such as ionizing radiation.
|Frank Comer, PhD||MedImmune|
Senior Scientist, Biosuperiors R&D
No bio available
|Richard Cooley, PhD||Oregon State University|
Assistant Professor, Biochemistry & Biophysics
The goal of my research program is to elucidate the structural basis by which post-translational modifications (PTMs) regulate cellular signaling systems. A long-standing challenge that has hindered progress in this field is our inability to programmably produce biologically relevant, multiply-modified proteins in sufficient quantities and homogeneity for structural biology applications. Genetic Code Expansion is a unique technology that enables co-translational installation of PTM amino acids into proteins at genetically programmed sites, but poor efficiency, premature protein truncation and mis-incorporation of natural amino acids have limited its broad utility. My laboratory aims to develop improved core GCE technologies for efficient and accurate incorporation of PTMs and their analogues into biologically relevant protein complexes for structural and biochemical characterization. Given the countless diseases associated with mis-regulation of PTM-proteins and a sobering lack of structural knowledge about them, this research hopes to facilitate future development of drugs and anti/nanobodies that target these pathways.
|Christopher Corbeil, PhD||Natl Research Council Canada|
Research Officer Molecular Modelling, Human Health Therapeutics
Dr. Christopher Corbeil is a Research Officer at the National Research Council Canada (NRC) who specializes in the development and application of computational tools for biotherapeutic design and optimization. He also teaches classes in Structure-Based Drug Design at McGill University. After receiving his Ph.D. from McGill University, he joined the NRC as a Research Associate investigating the basics of protein-binding affinity. Following his time at the NRC he joined Chemical Computing Group as a Research Scientist developing tools for protein design, structure prediction and binding affinity prediction. He then decided to leave private industry and rejoin NRC with a focus on antibody engineering. Dr. Corbeil has authored 25 scientific articles and is the main developer of multiple software programs.
|Colin Correnti, PhD||Fred Hutchinson Cancer Research Center|
Senior Research Scientist, Clinical Research
My research has always been at the interface of biophysics and immunology and has focused on developing new platform technologies that empower both basic scientists and clinicians to bring new biologics into the clinic. Supporting this I co-developed a robust lentiviral-based protein expression platform called Daedalus, which has completely revolutionized the speed at which we can bring new protein-based biologics into and through preclinical studies. Using this platform, I founded the Molecular Design and Therapeutics Core, which brings these technologies to every investigator at the Fred Hutchinson Cancer Research Center. I now support over a dozen preclinical pipelines with novel, custom-engineered proteins ranging from novel antibody therapeutics to knottin-based peptide-drug conjugates. I now have over 12 years of experience in protein engineering and biophysics, and 5 years of experience managing a highly productive, mammalian protein expression core, which provides not only next generation proteins to investigators but also a rich training environment for research technicians, graduate students and post-doctoral fellows. Currently I lead multiple immunotherapy drug discovery efforts that involve antibody discovery and engineering for CAR- T cell and bispecific therapies.
|Alison Crawford, PhD||Regeneron Pharmaceuticals Inc|
Senior Staff Scientist, Oncology & Angiogenesis
Dr. Crawford is a Senior Staff Scientist in the department of Oncology and Angiogenesis at Regeneron Pharmaceuticals, Inc where she has worked since 2011. She completed her BSc in Immunology from Glasgow University before being admitted to the Wellcome Trust PhD program at Edinburgh University where she focused on T cell memory. Her post-doctoral work at the University of Pennsylvania examined T cell exhaustion during chronic viral infection and the role of checkpoint inhibition in alleviating T cell exhaustion. This piqued her interest in immunotherapies and she made the transition into industry at Regeneron Pharmaceuticals where she currently leads a group developing pre-clinical models to examine bispecific antibodies targeting solid tumors. She led the in vivo pre-clinical research efforts on REGN4018 (MUC16xCD3) to advance the antibody through to IND submission.
|Conrad Russell Cruz||Childrens Natl Health System|
Director, Translational Research Labs & Assistant Professor, Center for Emerging Technologies Immune Cell Therapy
Dr. Cruz is an Assistant Professor at Children's National Hospital in Washington DC, with over a decade's experience working on cell-based therapies for cancer and infectious disease. He is currently developing NK cell and T cell-based therapies (both expanded and gene modified) for brain tumors and HIV.
|Zhenling Cui, PhD||Queensland University of Technology|
Research Officer, Science & Engineering
Dr. Zhenling Cui is a research associate at the Queensland University of Technology (Australia). She completed her PhD degree in Chemical and Biological Sciences at the University of Queensland in 2016 and then received Dean’s received Dean’s award for outstanding higher Degree by research. Her research interest lies in the field of protein engineering, synthetic biology and genetic code expansion technology. Her research has focused on exploiting redundancy of the genetic code and she has made significant contributions primarily to understanding the role of synthetic transfer RNAs (tRNAs) and their usage in terms of adapting the connection between sense codons and various unnatural amino acids with bio-orthogonal groups for future application in producing cyclized peptides, antibody drug conjugates (ADCs) and probes for structural conformation analysis.
|Hussain Dahodwala, PhD||University of Delaware|
PostDoc Researcher, Delaware Biotechnology Institute
Hussain Dahodwala obtained his PhD from RPI in 2007 and has since worked at SUNY polytech, NIH VRC labs and University of Delaware where the his research efforts have focused on understanding the role of culture conditions and cell physiology on living systems used for industrially relevant processes. The primary area of interest is the use of mammalian cell systems for the production of therapeutic proteins. He has many publications and review articles on the use of modern cell and molecular biology along with “omics” to probe physiological states, with an objective of optimizing production systems both from an engineering perspective (e.g. culture conditions) as well as from a biological perspective (cellular and metabolic engineering).
|Tony Joseph D'Alessio||Novartis Institutes for BioMedical Research Inc|
Senior Research Investigator/Lab Head, Oncology Biotherapeutics
Tony D’Alessio is a Senior Research Investigator and Lab Head in the Oncology Biotherapeutics group at the Novartis Institutes for Biomedical Research where he works on antibody drug conjugates and other novel biologics-based therapeutic approaches to targeting tumour and immune cells. Prior to Novartis he held positions at Igenica, Inc. and the Janelia Farm Research campus of HHMI.
|Claire Davies||Genzyme Corp A Sanofi Co|
After obtaining her PhD from the University of London in 2001, Claire Davies performed her postdoctoral work at the William Harvey Research Institute (WHRI) at Bart’s and The London, Queen Mary's School of Medicine and Dentistry and Joslin Diabetes Center, Harvard Medical School, Boston. Over the last 16 years, Dr Davies has led analytical and CMC teams in product development and analytical method development and validation. Currently, Dr Davies leads Bioanalytics, a group responsible for developing methods and strategies to support process development, product characterization and release and stability testing for therapeutic proteins and gene therapy products in preclinical and clinical development.
|Rupert Davies||Zymeworks Biopharmaceuticals Inc|
Director, Translational Sciences
Dr. Rupert Davies currently serves as a Director within Translational Sciences at Zymeworks, where he is responsible for the development of drug candidates from the hit discovery stage through to IND-enabling studies and into FIH clinical trials. Dr. Davies was part of the Zymeworks team that enabled the advancement of ZW25 and ZW49 into the clinic and he and the team are now focused on combining Zymework’s Azymetric™ Bispecific and ZymeLink™ Antibody Drug Conjugate (ADC) platforms to develop drug candidates with expanded therapeutic windows. Throughout his career, he has worked on a broad array of drugs modalities from small molecules and peptides to RNA mimics and antibodies, including five candidates that are currently being evaluated in clinical trials and two approved drugs. Prior to his current role, Dr. Davies worked in various roles at small start-ups, medium-sized biotechs and Amgen. He received his PhD in Bioengineering from the University of Utah and completed a post-doctoral fellowship in Bioengineering at the University of Washington.
|Jonathan Davis, PhD||Invenra Inc|
Head of Innovation, Innovation & Protein Engineering
Jonathan Davis, PhD is Head of Innovation at Invenra, Inc. Headquartered in Madison, Wisconsin, Invenra is focused on discovery and development of human IgG-like multispecific antibodies for immuno-oncology and autoimmune disorders. A thought leader in the field of bispecific antibodies for over a decade, Dr. Davis has 18 years of industry experience (Bristol-Myers Squibb, EMD Serono) as a protein engineer and platform developer focusing on antibodies and multispecific biotherapeutics, covering a wide variety of therapeutic areas. Dr. Davis holds a PhD in biophysics from UC San Francisco, which he followed with a postdoctoral fellowship at Harvard Medical School.
|JanWillem De Gier, PhD||Stockholm University|
CSO Xbrane Bioscience AB & Associate Professor, Center for Biomembrane Research
Jan-Willem de Gier is Professor of Biochemistry at Stockholm University. Main interest of his laboratory is the creation of E. coli recombinant protein production strains. To this end both evolutionary and engineering approaches are used. In addition, he is co-founder of the biotechnology companies Xbrane Biopharma AB and Abera Bioscience AB.
|Kim De Keersmaecker, PhD||Catholic University Leuven|
Assistant Professor & Head, Lab for Disease Mechanisms in Cancer
Kim De Keersmaecker obtained a PhD in the field of cancer biology at KU Leuven (Belgium) in 2008. From 2008 till 2010, she performed postdoctoral research at Columbia University (New York, USA) with Prof. Adolfo Ferrando, studying the role of transcription factor TLX1 in T-cell leukemia. During a second postdoc at KU Leuven (2010-2013), she undertook exome sequencing in T-cell leukemia patients and discovered somatic mutations in ribosomal proteins in cancer. In 2014, Kim received an ERC starting grant and established an independent research lab at KU Leuven studying the role of somatic ribosome mutations in cancer. The excellence of her research is illustrated by publications in leading journals such as Nature Genetics, Nature Medicine, Nature Communications and Molecular Cell.
|Brandon DeKosky||University of Kansas|
Assistant Professor, Chemical & Petroleum Engineering
Dr. Brandon DeKosky is an Assistant Professor at the University of Kansas Departments of Chemical Engineering and Pharmaceutical Chemistry, where his laboratory leverages recent advances in next-generation DNA sequencing technologies to achieve a more comprehensive understanding of immune function and accelerate the development of new vaccines and therapeutics. During his graduate research, Dr. DeKosky invented the very first technology for sequencing the antibody proteins encoded by B cells at the single-cell level, at a massive scale (for example, over 5 million single B cells in a one-day experiment), which reduced cost and enhanced throughput for antibody sequencing by multiple orders of magnitude compared to traditional antibody discovery platforms. Dr. DeKosky also pioneered the associated bioinformatic methods for rapid statistical analysis of the very large datasets generated by this approach. Ongoing efforts in the DeKosky lab, supported by an NIH Director’s Early Independence Award and a United States Department of Defense Career Development Award, and focus on expanding our ability to determine the mechanisms of protection for human vaccines and to develop novel and improved targeted human therapeutics.
|Stephen Demarest, PhD||Lilly Research Labs|
Research Advisor, Protein Biosciences
Steve leads a group at Lilly responsible for the design, engineering, and mechanistic characterization of proteins, antibodies, and antibody-like molecules. Prior to joining Lilly in 2011, Steve held positions at Biogen Idec, Diversa Corp, and Syngenta working as a Protein Chemist/Engineer on antibody and protein therapeutics design and biochemistry. Steve performed his graduate work at SUNY Stony Brook studying protein folding mechanisms. Steve was a NIH sponsored postdoctoral fellow at the Scripps Research Institute studying the structure, folding, and binding of nuclear co-activator proteins.
|Mahendra Deonarain, PhD||Antikor Biopharma Ltd|
Chief Executive and Science Officer
Dr Deonarain studied at Imperial College and Cambridge University where he carried out PhD research into protein engineering. From 1997-2011 Dr Deonarain was a Principle Investigator at Imperial College in Antibody Technology, which led to some novel technologies being developed commercially. Dr Deonarain now retains an honorary position. He has published over 80 papers and patents in protein/antibody engineering/conjugates. In 2014, he co-founded Antikor Biopharma where he is the CEO leading a team to develop the next-generation of antibody-fragment based ADCs.
I have spent most of my Biopharma career involved in protein biochemistry. I started in the early 2000’s at Wyeth, purifying proteins for structural studies. I then joined the Structural Protein Chemistry (SPC) group at Genzyme in 2010 where my main focus was using a variety of analytical techniques to define protein structure-function relationships. I left the group in 2013 to work for Warp Drive Bio. I mainly focused on mass spec proteomics for target identification and high-throughput mass spec screening methods for candidate compounds. I re-joined the SPC group, now known as the Characterization Group for Sanofi, in early 2016 and am using automation to support high throughput analytics.
|John Desjarlais, PhD||Xencor Inc|
CSO & Senior Vice President Research
Dr. Desjarlais is the Senior Vice President, Research and CSO at Xencor, Inc. Since joining Xencor in 2001, Dr. Desjarlais has overseen the company’s engineering, discovery, and preclinical work on antibodies and other proteins. With his coworkers, Dr. Desjarlais has developed several novel technologies for the optimization of antibodies and other proteins, including a platform for generation of bispecific antibodies, and has led the discovery of multiple therapeutic antibody candidates, including CD3 bispecific antibodies, checkpoint bispecific antibodies, and cytokine-Fc fusions for treatment of a variety of diseases. Dr. Desjarlais oversees all of Xencor’s discovery research and preclinical activities, from project conception and candidate generation through preclinical proof-of-concept and early development. Prior to Xencor, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University (1997-2001), where he developed and tested methods for the de novo design of protein sequences. He began his work in the field of protein design as a Jane Coffin Childs Fellow at UC Berkeley. Dr. Desjarlais holds a PhD in Biophysics from the Johns Hopkins University and a BS degree in Physics from the University of Massachusetts, Amherst.
|Gundo Diedrich, PhD||MacroGenics Inc|
Associate Director, Antibody Engineering
Gundo Diedrich received his PhD in Chemistry from the Max-Planck Institute for Molecular Genetics in Berlin. He completed his postdoctoral training in immunology at Yale University, and worked as a Research Scientist in antibody discovery at Targeted Molecules, diaDexus, and Medimmune. In 2015, he joined MarcoGenics as Director Antibody Engineering.
|Julia Ding||Bristol Myers Squibb Co|
Director, Process Developmentelopment Analytical & Analytical Developmentelopment
Julia Ding is a director of process analytics and analytical development at Bristol Myers Squibb Devens site. She is leading a diverse and dynamic team responsible for enabling analytics for bioprocess development and characterization, analytical development and assay development in advancing CMC control strategy and developing new technologies , such as PAT for next generation biologic process. Julia Ding also serves in BMS biologic specification committee and comparability council.Prior to joining Bristol Myers Squibb, Julia Ding was a manager at PPD leading a multifunctional analytical development team in quality control testing, assay development, assay validation, assay life cycle management, and product characterization. Julia obtained her Ph.D. in physical organic chemistry from Emory University and postdoc from University of California at Berkeley.
|Benjamin Doranz, PhD, MBA||Integral Molecular Inc|
President & CEO
Ben Doranz (President and CEO, Integral Molecular) has expertise in membrane proteins and antibodies, with 80+ publications, in journals including Cell, Science, and Nature. Dr. Doranz cofounded the company and has led all aspects of the company’s growth since its inception, bringing five different technologies from research to market.
|Chester Drum, MD, PhD||Natl University of Singapore|
Prof. Drum received an MD PhD from the University of Chicago. After a post-doc in Robert Langer's lab at MIT, he moved to National University of Singapore as a faculty where he studies protein engineering and novel methods of protein folding. While at MIT, he received the Burroughs Wellcome Career Award for Medical Scientists. In Singapore, he has been a recipient of the Clinician Scientist Award from the National Medical Research Council.
|Zhimei Du, PhD||Merck & Co Inc|
Director, Bioprocess Development
Zhimei Du earned a Ph.D. from Cornell University Medical College, Immunology Program, studying molecular mechanisms in tumor immunology and autoimmune disease areas. After graduation, she joined Robert G. Roeder’s laboratory at Rockefeller University, studying protein chemistry and epigenetic regulation mechanism. She was later recruited by Regeneron’s bi-specific antibody engineering group. Later, she joined Amgen’s Cell Sciences & Technology department, focusing on cell line and Upstream process development. She then joined Teva Pharmaceuticals building the Upstream development team and labs for innovative biologics pipelines. Currently she is the director of Bioprocess at Merck, leading cell line development, cell banking, and cell therapy process development team. She is also the leader and core member of multiple Industrial-wide Consortium teams, setting up road map and establishing industrial common practices in various biotherapeutics development areas, including ADC/Bispeicifics team at BPOD/NIMBLE, IQ comparability team, IQ sequence variant consortium team, IQ and BPOD monoclonality consortium team.
|Takashi Ebihara, PhD||GeneFrontier Corp|
Takashi is COO of GeneFrontier Corporation (GFC) since 2010. Takashi got his PhD for the research of cell-free protein expression system at Tokyo Institute of Technology in 2000 and joined in VC in life science industry. At 2003, Takashi was involved in establishment of GFC and fully committed to business development of GFC from the beginning.
|Wafik El-Deiry, MD, PhD, FACP||Brown University|
Professor, Pathology & Lab Medicine
Wafik El-Deiry, MD, PhD, FACP is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is a Professor of Pathology and Laboratory Medicine, Professor of Medical Science, and Mencoff Family University Professor at Brown. He previously served as Deputy Director for Translational Research, co-Leader of the Molecular Therapeutics Program, Professor of Oncology, and the William Wikoff Smith Endowed Chair in Cancer Research at Fox Chase Cancer Center. From 2010 through 2014, Dr. El-Deiry was the Rose Dunlap Professor of Medicine and Chief of Hematology-Oncology at Penn State. In 2009, El-Deiry became an American Cancer Society Research Professor. He earned MD/PhD degrees from University of Miami School of Medicine and completed internal medicine residency and medical oncology fellowship at the Johns Hopkins Hospital and the Johns Hopkins Oncology Center. El-Deiry has >400 peer-reviewed publications and 5 edited books. In 2019, his H-index is 111 and he has >66,000 citations in Google Scholar. A practicing Oncologist, his scientific expertise is in cell death, drug resistance in cancer and drug discovery and development. Dr. El-Deiry has trained many students and post-doctoral fellows, physician-scientists, and continues to mentor junior scientists and faculty in basic and translational cancer research.
|Stacey Elliott, PhD||RheoSense Inc|
Principal Scientist, Research & Development
Dr. Stacey Elliott is a Principal Scientist with RheoSense, Inc. She has an extensive experience in the rheology of colloid and polymer systems during her previous positions at Alcon & Dupont. She is excited to work with our customers to advance the analysis and interpretation of protein rheology beyond the models currently adopted from dispersions and synthetic polymers.
|Peter Ellmark||Alligator Bioscience AB|
Vice President Discovery
Peter Ellmark joined Alligator Bioscience in 2008 and is VP Discovery since 2018. He holds a PhD and an associate professorship in Immunotechnology at Lund University and has more than 15 years’ experience of developing antibodies for immunotherapy of cancer. Dr. Ellmark´s research interest is focused on developing mono- and bispecific antibodies for tumor directed immunotherapy of cancer.
|M Frank Erasmus, PhD||Specifica Inc|
M. Frank Erasmus is the head of bioinformatics at Specifica, Inc. where he specializes in the use of Next-Generation Sequencing technologies to aid in the design of custom therapeutic antibody libraries. Formerly, Frank was awarded a national fellowship from the National Cancer Institute for his translational research associated with B cell precursor acute lymphoblastic leukemia conducted at the Spatiotemporal Modeling Center and Los Alamos National Labs. He brings over 10 years of experience in both biotechnology and academic settings in the development and characterization of therapeutic antibodies using theoretical modeling, bioinformatics and experimental approaches.
|Soldano Ferrone, MD, PhD||Massachusetts General Hospital|
Professor in Residence
Soldano Ferrone received his MD and PhD degrees in 1964 and in 1971, respectively, from the University of Milan, Milan, Italy. He has held faculty positions at the University of Milan, Milan, Italy, Scripps Clinic and Research Foundation, La Jolla, CA, Columbia University, New York, NY, New York Medical College, Valhalla, NY, Roswell Park Cancer Institute, Buffalo, NY and at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Since 2012 he is a faculty member of the Department of Surgery at Massachusetts General Hospital, Harvard Medical School, Boston, MA. Dr. Ferrone has received many awards and honors. For the last 30 years he has been the member of many review committees including NIH Study Sections, and of the editorial boards of many scientific journals. Furthermore, he is the member of several external scientific advisory boards. Dr. Ferrone’s research program focuses on the molecular characterization of escape mechanism(s) utilized by tumor cells to avoid immune recognition and destruction and on the development of combinatorial immunotherapeutic strategies to counteract the escape mechanism(s) utilized by tumor cells. These studies are greatly facilitated by the large panel of HLA antigen- and human tumor antigen-specific monoclonal antibodies he has developed and shared with the scientific community over the years. He has described the results of his studies in more than 600 papers published in peer reviewed journals. Moreover, he has been the editor of 14 books and the guest editor of 5 special issues of oncology journals.
Jonny Finlay is the CEO of UltraHuman, an antibody drug discovery biotech in the UK that is developing a series of therapeutics for inflammation and oncology. Prior to co-founding UltraHuman, Jonny led research teams in Biologics Discovery at Pfizer and Wyeth and carried out postdoctoral research in recombinant protein engineering at several institutes, including the Centre for Biologics Evaluation and Research, FDA.
|Corinna Fiorotti, PhD||BioAgilytix|
Corinna Fiorotti obtained her Ph.D. in Microbiology and Immunology from the University of New Hampshire before attending Harvard Medical School. Since, she has served as a faculty member at Harvard and has held scientific leadership positions at Eyetech and Pfizer where she focused on developing cell-based assays for the detection of neutralizing antibodies, ADA, and PK assays. She joined BioAgilytix in 2015 as a Business Development Director and was promoted to Scientific Officer in 2019.
|Nicolas Fischer, PhD||NovImmune SA|
After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry) at the Medical Research Council in Cambridge (UK) to work on in vitro evolution of proteins and antibody engineering. At Novimmune since 2002, he led several therapeutic antibody programs. Then, as the Head of Research, he focused on the development of the λ body bispecific antibody platform which is now the core technology of Light Chain Bioscience.
|David Fitzgerald||NIH NCI|
David FitzGerald, PhD serves as Chief of the Biotherapy Section, Laboratory of Molecular Biology, CCR, NCI. His undergraduate degree was from Trinity College, Dublin, Ireland and he received his PhD from the U of Cincinnati. Dr FitzGerald has a life-long interest in antibody-based therapies with particular emphasis on the development of cytotoxic antibodies for treating cancer. He has played pivotal roles in both the development of recombinant immunotoxins and the use of combination treatments to make immunotoxins more effective. Because of the need to ‘kill’ cancer cells, Dr FitzGerald and his team also have a keen interest in apoptosis and cell death pathways, attempting to identify biomarkers that predict sensitivity and resistance to various antibody-based therapeutics.
|Amanda Fitzgerald, PhD||Genedata Inc|
Senior Scientific Consultant, Biologics
Amanda Fitzgerald leads a team of scientific consultants at Genedata, who provide solutions for organizations with large molecule and data management needs. She received her doctorate in Biochemistry and Molecular Pharmacology from the University of Massachusetts Medical School and has pharmaceutical industry experience in biotherapeutic discovery and production groups, including scientific support for strategic alliances and development of a high-throughput protein production platform at Pfizer.
|Daron Forman||Bristol Myers Squibb Co|
Daron Forman is currently a Principle Scientist within the Discovery Biotherapeutics Department of Bristol Myers Squibb. For the last 10 years he has helped to setup an immunogenicity risk assessment core group which utilizes in silico, in vitro and in vivo tools to help select lead drug candidates for further development. He earned dual Bachelor of Arts degrees in Biology and Psychology at the University of Rochester and then joined the lab of Dr. Aldo Rossini at the University of Massachusetts Medical School for his PhD work investigating the effects of viral infection on stem cell transplantation tolerance. After completing his PhD in Immunology and Virology, he joined the lab of Dr. John Iacomini at Harvard University for his post-doctoral work examining mechanisms by which T cells are rendered tolerant in mice reconstituted with retrovirally transduced bone marrow. Prior to BMS, Daron worked at Tolerx trying to understand the mechanisms of action of humanized anti-CD3 and anti-GITR monoclonal antibodies, as well as work on identifying biomarkers for both programs.
|Jen Fox, PhD||AstraZeneca|
Scientist, Bioassay, Impurities and Quality, Analytical Sciences
No Bio Available
|Amber Fradkin||KBI Biopharma|
Director, Particle Characterization Core Facility
Amber received her PhD in Chemical Engineering within the Pharmaceutical Biotechnology Program with a specialization in the field of immunogenicity of therapeutic protein aggregates at the University of Colorado at Boulder. Amber also holds a Masters in Science from the University of Colorado at Boulder plus a Bachelors of Science from the Colorado School of Mines. She currently holds the position of Director at KBI Biopharma where she manages the Particle Characterization Core which specializes in analytical methods for quantifying, characterizing and identifying submicron, subvisible and visible particulates. Previously, at Amgen, Amber was a Scientist within the biomolecular structures and interactions group where she supported biophysical characterization of protein products with a specialty in subvisible particle characterization and identification. Prior to Amgen, Amber’s experiences include analytical and formulation development for Merck & Co. and collaborations with BaroFold, Inc. to employ high hydrostatic pressure to refold proteins and control subvisible particles.
|Arthur Frankel, MD||University of South Alabama|
Dr. Frankel is the inaugural holder of the Arlene and Mayer Mitchell Chair in Medical Oncology. He is a co-inventor on 12 issued patents and has authored or co-authored more than 200 publications in peer-reviewed journals. His current research interests include melanoma, for which he is nationally renowned.
|Alex Franzusoff||PACT Pharma Inc|
Dr. Franzusoff has led PACT Pharma since 2017, developing personalized adoptive T cell therapies using precision genome-engineered patient T cells that target confirmed tumor neoepitopes.
Alex has actively contributed to significant advances in immuno-oncology (I-O). As SVP R&D at Bavarian Nordic, his team’s work on cancer vaccines and combination I-O therapies was key to the $1B deal with BMS in 2015. Dr. Franzusoff earlier co-founded GlobeImmune, where he served as VP R&D, developing immunotherapy against cancer & infectious diseases. In Boston, Alex was CEO & Director for AZTherapies, developing Alzheimer’s combination drug therapies for Phase 3 studies. He previously led the venture-backed Permeon Biologics developing intracellular biologics. Alex was tenured professor at the Univ. of Colorado Medical School until 2004. Dr. Franzusoff received his PhD in Biochemistry from SUNY Stony Brook, NY. Dr. Franzusoff trained as a postdoctoral fellow at the EMBL in Heidelberg, at the ETH in Zurich, and as a postdoctoral fellow with the Nobel Laureate, Dr. Randy Schekman, at UC Berkeley.
|Masha Fridkis-Hareli||ATR LLC|
Founder & President
Masha Fridkis-Hareli, MSc, PhD, is an immunologist, consultant and inventor with over 20 years of experience in academia and industry. She is a Founder and President of ATR, LLC, a translational research company providing scientific consulting and laboratory services in immunoassay development to research institutions and the biotechnology industry. During her post-doctoral training at Harvard University, she designed and developed a group of novel compounds for treatment of autoimmune diseases. After serving as Principal Investigator at the Dana-Farber Cancer Institute, Dr. Fridkis-Hareli transitioned to industry where she held a variety of positions with increasing responsibilities at Resolvyx Pharmaceuticals, Charles River Laboratories, Taligen Therapeutics and Alexion Pharmaceuticals. Dr. Fridkis-Hareli is a co-author of over 100 publications and 17 issued patents. She is an adjunct professor at the Harvard Extension School, Northeastern University, Worcester Polytechnic Institute and Framingham State University, where she teaches biotechnology and immunology courses at the graduate biotechnology programs.
|Simon Friedensohn||ETH Zurich|
Graduate Student, Biosystems Science & Engineering
Simon Friedensohn is a PhD candidate in Sai Reddy’s Laboratory of Systems and Synthetic Immunology at ETH Zurich. His research work focuses on developing both experimental as well as computational methods for high-throughput immune repertoire sequencing. He holds a BSc and MSc in Biotechnology from ETH Zurich. Previous to joining the Reddy lab, he completed a scientific internship at Roche where he worked on high-throughput (mi)RNA profiling for comparative genomics.
|Terry Fry, MD||University of Colorado Denver|
Dr. Fry is a Professor of Pediatrics, Hematology and Immunology, Co-Director of the Human Immunology and Immunotherapy Initiative, Director of Cancer Immunotherapy at the University of Colorado School of Medicine and holds the Robert and Kathleen Clark Endowed Chair in Pediatric Cancer Therapeutics at the Children’s Hospital Colorado. He arrived at Children’s Hospital Colorado in 2018 after serving as Head of the Hematologic Malignancies Section in the Pediatric Oncology Branch at the NIH where he led efforts in Cellular Immunotherapy for pediatric leukemia. Prior to the NIH, Dr. Fry was Chief of Blood and Marrow Transplantation at Children’s National Medical Center in Washington, DC. Dr. Fry’s research focuses on the preclinical and clinical development of chimeric antigen receptor T cells for pediatric cancers. He serves on the Committee for Scientific Affairs for the American Society of Hematology, Vice Chair for Biology in the Cellular Therapy Committee of the Children’s Oncology Group and was recently elected into the American Society for Clinical Investigation.
Principal Scientist, Biologics Process Developmentelopment
Cexiong (Winston) Fu has more than 10 years of experience in the development of various biotherapeutics modalities, receiving his Ph.D from North Carolina State University. Winston is currently a Pharmaceutical Science Lead at Takeda and is leading the CMC development of biologics. Prior to joining Shire/Takeda in 2018, Winston has worked in Abbvie and Pfizer on biologics ADME, biosimilar analytical characterization, and ADC characterization and bioanalysis.
|Thomas Gaj||University Of Illinois Chicago|
Asst Prof, Bioengineering
Thomas Gaj is an assistant professor of bioengineering at the University of Illinois Urbana-Champaign. He received his Ph.D. in chemistry from the Scripps Research Institute in La Jolla, CA and performed his postdoctoral training at the University of California, Berkeley. His research lies at the intersection of neuroscience and engineering and is focused on the development of technologies that can facilitate the correction of the inherited and spontaneous mutations that underlie many neurodegenerative conditions.
|Rajkumar Ganesan||Janssen Pharmaceuticals Inc|
Director, Antibody Engineering, Bispecifics & CAR T
Raj Ganesan received his Ph.D. at the University of Zurich, Switzerland. Raj is a Protein/Antibody engineer with extensive industry experience (Genentech, MedImmune and Boehringer Ingelheim) in the Design, Development and Characterization of Monoclonal Antibodies, Multi-Specific Biologics and CAR-T. Since 2017, Raj is leading the pre-clinical discovery of biotherapeutics at Janssen R&D (Johnson and Johnson), primarily focused on bispecific antibodies and CAR-T therapies.
|Sandra Garces||Amgen Inc|
Medical Director, Global Drug Developmentelopment
Sandra Garces is Rheumatologist with more than a decade of clinical experience, focused on the use of biologic therapies in the treatment of patients with chronic inflammatory diseases. She did her PhD in the Gulbenkian Institute of Science with a thesis entitled “Clinical Relevance of Drug Immunogenicity”. She developed an algorithm that uses information on drug concentrations and immunogenicity to help guide therapeutic decisions towards more cost-effective therapeutic strategies in clinical practice. In 2016 she joined Eli Lilly & Co. where she has worked on the assessment of the clinical relevance of IMG across different programs. She recently joined Amgen as a clinical research director in 2019.
|Melissa Geddie, PhD||Biogen|
Senior Scientist, Antibody Discovery
No bio available
|Marvin Gee||3T Biosciences|
CoFounder & Head, Target Discovery
Biology at the California Institute of Technology in 2013, where he published and patented work engineering T cell receptors for adoptive T cell therapy in the laboratory of David Baltimore. Following, he received his Ph.D. in Immunology at Stanford University in the laboratory of K. Christopher Garcia in 2017, publishing work on technology to identify the specificities of T cell receptors for application in oncology and further work on the molecular- and systems biology-focused characterization of T cell receptor recognition of immunological targets. At Stanford, Marvin received his PhD degree with an additional core focus in Computational Immunology. Marvin has had prior work experience at the National Cancer Institute. His primary focuses are in immunology, structural biology, protein engineering, systems biology, bioinformatics, and algorithms for the application of therapeutic- and early- discovery in immuno-oncology. He is currently Head of Target Discovery at 3T Biosciences since co- -founding the company in 2017.
|Nimish Gera, PhD||Mythic Therapeutics|
CoFounder & Director R&D
Nimish Gera is the Director of Research and Development at Mythic Therapeutics leading multiple projects to engineer and develop novel antibody and antibody-based drugs in oncology and immuno-oncology. Prior to Mythic, Nimish has over ten years of experience in antibody and protein engineering with five years leading bispecific antibody programs in several disease areas such as rare diseases, oncology and immunology at Alexion Pharmaceuticals and Oncobiologics. Nimish received his PhD degree in Chemical and Biomolecular Engineering from North Carolina State University and a B.Tech degree in Chemical Engineering from Indian Institute of Technology, Guwahati.
|Scott Gerber||University of Rochester|
Assistant Professor, Surgery Research
Dr. Gerber is a tumor immunologist whose laboratory focuses on harnessing the immune system to recognize and kill cancerous cells. His lab uses an immunotherapeutic approach to enhance the efficacy of chemo/radiotherapies to control or even cure both primary and metastatic malignancies.
|Tariq Ghayur, PhD||Abbvie|
Distinguished Research Fellow, Foundational Immunology
Tariq Ghayur received his PhD (1987) in Immunology from McGill University, Montreal, Canada and did his post-doctoral training at McGill (1987-’88) and Dana Farber Cancer Institute (1988-’90). He joined AbbVie Inc. in 1990. Tariq has worked on both small molecule and therapeutic antibody discovery programs and from 1998-2004 led two therapeutic antibody discovery project teams and delivered 2 drug development candidates. From 2011-2016, Tariq led the dual variable domain Ig (DVD – Ig™) Initiative and the Novel Biologics group at AbbVie. Currently, he leads the Foundational Immunology group. In addition to therapeutic antibodies, novel biologic formats and antibody generation technologies, his areas of interest are inflammation, intracellular trafficking, antigen processing and presentation, lymphocyte biology, cytokine biology and glyco-biology.
|David Gifford||Massachusetts Institute of Technology|
Professor, EleCenterical Engineering & Computer Science
David Gifford leads combined computational and experimental programs that apply machine learning to therapeutic development. His laboratory has developed machine learning methods for designing the complementarity-determining regions of human antibodies that allows for the simultaneous optimization of antibody affinity and target specificity; the discovery of CRISPR gRNAs that can repair disease phenotype without a repair template; and the discovery of novel differentiation conditions to guide stem cells to desired therapeutic fates. He is Professor of Electrical Engineering and Computer Science and Professor of Biological Engineering at MIT, an Affiliate Member of the Whitehead Institute, and Affiliated Faculty of the Harvard Stem Cell Institute.
|Avinash Gill||Genentech Inc|
Senior Scientific Manager, Antibody Engineering
Avinash Gill received his Ph.D. in Biochemistry and Structural Biology from Dartmouth College and completed his post-doctoral research at the Thayer School of Engineering at Dartmouth. In his previous roles, he has worked at ImmunoGen, Bio-Architecture Lab and Sutro Biopharma. His research interests include protein purification, biochemical assay development, protein engineering, affinity analysis, automated process development and bioinformatics. Currently he is Sr. Scientific Manager in the Antibody Engineering department at Genentech where he oversees efforts in automated high-throughput protein production, design, implementation and maintainence of automated workflows for antibody discovery and engineering, as well as software development for efficient process management. His research group focuses on developing and implementing automated high-throughput technologies for production and characterization of naturally derived and engineered antibodies, antibody fragments as well as other novel therapeutic formats.
|William Gillette, PhD||Leidos Biomedical Research Inc|
Principal Scientist Protein Expression Lab, Cancer Research Technology Program
I am currently leading the recombinant protein production efforts of the RAS Initiative at the Frederick National Laboratory in Frederick, MD.
|Robert Giugliano||Brigham & Womens Hospital|
Physician, Cardiovascular Medicine
Dr. Giugliano, MD is a Senior Investigator with the TIMI Study Group, Staff Physician in the Cardiovascular Division at Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School.
He graduated Summa Cum Laude, Phi Beta Kappa (Mathematics) from Dartmouth College (1985), receiving a medical degree at Harvard Medical School (1989). Dr. Giugliano completed residency and chief residency at Cedars-Sinai Medical Center (UCLA affiiliate,1989-93) and cardiology fellowship at Massachusetts General Hospital (1993-6).
In 1996, Dr. Giugliano joined the Brigham and Women’s Hospital as a Medicine Research Fellow in the Thrombolysis in Myocardial Infarction (TIMI) Study Group directed by Eugene Braunwald, and completed a Science Masters (Epidemiology) at the Harvard School of Public Health. In 1997, he joined the Cardiovascular Division faculty of the Brigham and Women’s Hospital and has served as the principal investigator for 9 multicenter clinical trials at TIMI.
His areas of research interests include novel antithrombotic, fibrinolytic agents, and lipid-lowering therapies, and patient outcomes following Acute Coronary Syndromes (ACS). He has authored more than 400 articles and chapters, and delivered hundreds of lectures. Dr. Giugliano is the Principal Investigator for the VESALIUS-CV trial of the PCSK9 inhibitor evolocumab in patients at high risk for cardiovascular events with no prior MI or stroke, and also the ENGAGE-AF TIMI 48 trial of the factor Xa inhibitor edoxaban in 21,105 patients with fibrillation. He is also a member of the Operations Committees and Lead TIMI Investigator for the FOURIER trial studying evolocumab in 27,564 hyperlipidemic patients with prior cardiovascular disease; the IMPROVE-IT trial evaluating ezetimibe in 18,144 patients post ACS; and the EARLY ACS trial of eptifibatide in 9492 patients with ACS.
Dr. Giugliano serves on numerous Data Safety Monitoring Boards, clinical endpoint committees, and Holter/ECG Core Laboratories. He actively participates in the clinical activities of the Cardiovascular Division, attending in the Levine Cardiac Intensive Care Unit, telemetry unit, and consult services, and sees patients in a busy growing outpatient practice.
|Charles Glabe||University of California Irvine|
Professor, Molecular Biology & Biochemistry
I received my PhD in 1978 from UC Davis and trained as a postdoctoral fellow at the Johns Hopkins University School of Medicine and UC San Francisco. I have been a professor at UC Irvine since 1985. The focus of my laboratory is to understand the structure of amyloids, their assembly pathways and their mechanisms of pathogenesis in neurodegenerative disease, like Alzheimer’s disease. The goal of this work is to facilitate the development of effective diagnostic and therapeutic agents. Amyloids form an ensemble of common structures, including parallel, in-register fibrils, anti-parallel ß sheet prefibrillar oligomers and ß barrel annular protofibrils that display generic epitopes that are recognized by polyclonal and monoclonal antibodies in a wide variety of amyloid forming proteins and peptides. We have raised 30 unique monoclonal antibodies that react with different epitopes and recognize different structures and aggregation states. This raises the question of whether these different amyloid structures have distinct functions in pathogenesis. Using these novel antibodies, we have discovered that unique types of amyloid deposits accumulate at specific times and locations during aging and disease such as intracellular amyloid which aggregates early inside neurons that ultimately degenerate and form the nidus of neuritic plaques. We are currently investigating these novel amyloid structures to determine their significance for disease processes and their mechanisms of pathogenesis. We are also characterizing endogenous human antibodies that are associated with protection against Alzheimer’s disease, infectious disease and cancer.
|Jacob Glanville||Distributed Bio|
Founding Partner & CEO
Jake Glanville is an entrepreneur and computational immuno-engineer. He has developed multiple seminal methods in the fields of high-throughput antibody repertoire sequencing, repertoire decoding algorithms, single-cell TCR receptor & phenotype sequencing, and computationally guided antibody library engineering.
|Jochem Gokemeijer||Bristol Myers Squibb Co|
Associate Director Preclinical Discovery & Development
Jochem has been at Bristol-Myers Squibb for 14 years in different roles of responsibility focused on biologics drug development. For the last 8 years he has been focused on building a group for pre-clinical immunogenicity risk assessment and mitigation. He received his training at the University of Groningen and the Dana Farber Cancer Institute.
|Joel Goldstein, PhD||Celldex Therapeutics Inc|
Senior Director R&D
Joel Goldstein received his PhD in molecular biology from the University of Medicine and Dentistry of New Jersey (UMDNJ) in 1991. He then did his postdoctoral work at Bristol-Myers Squibb (BMS) on antibody fusion proteins prior to joining Medarex in 1994. His role at Medarex was initially to develop bispecific antibodies and fusion proteins, which then evolved into developing antibody production platforms for manufacture. Joel moved back to BMS in 2009 where he continued to lead a team developing manufacturing cell lines for the company’s biologics programs. He then joined Celldex Therapeutics in 2014 to help manage R&D efforts, including establishing antibody engineering and bispecific antibody design strategies for the company’s pipeline.
|Tamir Gonen, PhD||University of California Los Angeles|
Director, MicroED Imaging Center & Professor, Biological Chemistry & Physiology
Tamir Gonen is a membrane biophysicist and an expert in electron crystallography and cryo EM. Gonen is a professor of Biological Chemistry and Physiology at the David Geffen School of Medicine of the University of California, Los Angeles and an Investigator of the Howard Hughes Medical Institute and a Member of the Royal Society of New Zealand. In 2011, while leading a lab at the HHMI Janelia Research Campus he began developing Microcrystal Electron Diffraction (MicroED) as a new method for structural biology. With this method, Dr. Gonen has pushed the boundaries of cryoEM and determined several previously unknown structures at resolutions better than 1Å. Gonen authored more than 100 publications and several of his past trainees are now faculty around the world at top universities.
|Maria Gonzalez-Pajuelo, PhD||Fairjourney Biologics SA|
Since 2012 Maria Gonzalez-Pajuelo is co-founder and Chief Scientific Officer at FairJourney Biologics, a company that provides fast and high quality solutions for monoclonal antibodies needs. Maria initiated her career in the antibody field in 2006 at Ablynx, where she worked on the identification of Nanobodies® as Scientist-Team leader until 2012. Maria is co-inventor in 13 patent applications on antibodies and on antibodies technologies and co-author on 13 Peer Reviewed Publications.
|Jonathan Gootenberg||Massachusetts Institute of Technology|
No bio available
|Boris Gorovits||Pfizer Inc|
Senior Director, Pharmacokinetics Pharmacodynamics & Metabolism
Boris Gorovits is a Senior Director of the Bioanalytical lab at Pfizer. Boris earned his PhD in Enzymology from the Moscow State University and later completed postdoctoral research studies in protein biophysics at the Medical Center, University of Texas at San Antonio, TX, USA. In 2000, Boris joined Wyeth Research (later Pfizer Inc) to work as a bioanalytical group lead with a growing scope of responsibilities. Currently, he leads the Bioanalytical group within Biomedicine Design department which is responsible for many aspects of the Regulated and Nonregulated Bioanalytical support for the pan-Pfizer Biotherapeutic portfolio. Boris co-chairs Pfizer internal Immunogenicity Expert Working Group, which is responsible for review of the biotherapeutic immunogenicity risk assessment and mitigation strategies. Recently, Boris has been actively involved in industry discussions focusing on PK and immunogenicity assessment, bioanalytical support of various biotherapeutic modalities, including mAbs, bi-specific antibodies, antibody–drug conjugates, ADCs and gene therapy. Boris is proud to be an active member of the American Association of Pharma Scientists.
|Ingo Gorr, PhD||Boehringer Ingelheim Pharma GmbH & Co KG|
Director & Head
Ingo Gorr received his Biology degree from the University of Wuerzburg in Germany, followed by a PhD in the Molecular Cell Biology department at the Max-Planck-Institute of Biochemistry in Martinsried/Germany. He then joined Roche first in Basel then in Penzberg and since 2015 he is leading the Early Stage Bioprocess Development (USP&DSP) at Boehringer Ingelheim in Biberach/Germany.
|Susanne Graslund, PhD||Karolinska Institute|
Senior Researcher, Medical Biochemistry & Biophysics
Susanne Gräslund did her doctoral training in Biotechnology at the Royal Institute of Technology in Stockholm, Sweden. After her dissertation in 2002 she worked for three years at Biovitrum AB in the Target Expression & Purification section. In March 2005, Susanne joined the newly started Structural Genomics Consortium group in Stockholm, heading the Biotechnology team responsible for the generic protein production pipeline. She was then recruited to the SGC Toronto site as Principal Investigator for the Biotechnology team in September 2011. In 2015, SGC established a new lab at Karolinska Institutet in Stockholm where Dr. Gräslund is now leading a new team to generate recombinant antibodies for target validation and research purposes.
|Ulf Grawunder, PhD||NBE Therapeutics|
CEO & Founder
Ulf Grawunder is an experienced Swiss Life-Science entrepreneur with over 10 years experience in the therapeutic antibody development industry. With NBE-Therapeutics, he has recently founded his second Swiss Biotech company and is leading NBE-Therapeutics as its CEO since June 2012. Ulf Grawunder has invented two new patent-pending technologies at NBE-Therapeutics that allow the company to develop most highly innovative antibody-based drugs, including next-generation antibody drug conjugates (ADCs) for the therapy of cancer. Before that, Ulf Grawunder co-founded the Swiss Biotech company 4-Antibody, recently sold to U.S.-based Agenus (AGEN), where since 2004 he served as founding CEO and after 2006 assumed the role of CSO. During his tenure at 4-Antibody, Ulf Grawunder raised about CHF 50 million capital for the company, secured two pharma/biotech collaborations with Boehringer Ingelheim, Germany, and Human Genome Sciences, U.S.A. and grew the company to 50 employees. Ulf Grawunder is serving on various Boards of non-profit and for-profit life-science organizations and is vice-president and Board member of the Swiss Biotech Association. Ulf Grawunder holds a PhD in Cell Biology from the University of Basel, for work on early B cell development performed at the Basel Institute for Immunology. In addition, Ulf Grawunder holds a Diploma in Technology Entrepreneurship from the Entrepreneur and Business School in St. Gallen, Switzerland (HSG=Hochschule St. Gallen).
|Claes Gustafsson, PhD||ATUM|
As ATUM’s Co-Founder and CCO, Dr. Gustafsson oversees most of the company's external communications. Prior to co-founding ATUM, Dr. Gustafsson led, managed and collaborated with key strategic teams at Maxygen Inc. Before Maxygen, Dr. Gustafsson worked as a scientist at Kosan Biosciences, a number of research, teaching, and post-doctoral positions at UCs Santa Cruz and San Francisco, and at University of Umeå. He received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden.
|Matias Gutierrez Gonzalez||University of Kansas|
Postdoc Researcher, Pharmaceutical Chemistry
Dr. Matias Gutierrez is a Postdoctoral Researcher in the lab of Dr. Brandon DeKosky at the University of Kansas. Dr. Gutierrez’s graduate research studied the development and characterization of biopharmaceuticals, with a focus on monoclonal antibodies. Currently, Dr. Gutierrez works to develop new tools for bioinformatic analysis of single-cell antibody repertoire data, and to establish new techniques for high-throughput B cell sequencing.
|Benjamin Hackel||University of Minnesota Twin Cities|
Associate Professor, Chemical Engineering & Materials Science
Ben Hackel is an Associate Professor of Chemical Engineering and Materials Science at the University of Minnesota. He earned degrees in chemical engineering from the University of Wisconsin (B.S. 2003, advised by Eric Shusta) and MIT (Ph.D. 2009, advised by Dane Wittrup) and performed postdoctoral research in the radiology department at Stanford University (Sam Gambhir). Since its inception in 2011, the Hackel lab has applied protein engineering technologies to develop physiological molecular targeting agents for molecular diagnostics and targeted therapy, with a focus on oncology and infectious disease.
|Mohamad Hamieh, PhD||Memorial Sloan Kettering Cancer Center|
PostDoc Fellow, Center for Cell Engineering
Dr. Hamieh received his PhD from Rouen University in France. Currently, he is a research associate in Dr. Michel Sadelain lab at Memorial Sloan Kettering Cancer Center in New York. His work focuses on understanding the dynamics of CAR T cell anti-tumor response mainly mechanisms governing resistance to CAR T cell therapy and developing approaches to enhance engineered T cells against cancer.
|Mei Han||Amgen Inc|
Scientist, Pharmacokinetics & Drug Metabolism
Mei has worked in biotech industry for 20 years after she obtain her MS from Dept of Chemistry and Biochemistry, Montana State University. She is currently a Senior Scientist in the Pharmacokinetics & Drug Metabolism (PKDM) department at Amgen South San Francisco. Over the years, she has worked in different functional areas across Amgen including Analytical Sciences, Protein Sciences and PKDM. Her experience ranging from chromatographic (such as SEC, CEX, HIC and RP-HPLC), electrophoresis (cIEF, CE-SDS, CE-MS) and mass spectrometry analytical method development, inter- and intra- departmental method transfer such as from Analytical Sciences to QC labs, involved in IND and BLA filing; she is also experienced in small and middle scale protein purification. She implemented Capillary Electrophoresis (CE) techniques into Protein Science and PKDM departments, developed an automated immunoaffinity capture (IA)-CE-MS intact mass analysis biotransformation workflow in PKDM department to support multiple pipeline projects ranging from antibodies, fusion proteins and antibody conjugates in vitro and in vivo as well as other characterization techniques. Currently she leads the large molecule ADME team within PKDM, interacting with Project Team Representatives to support projects and serve as resource for protein characterization, analytical method development, troubleshooting and experiment planning.
|Fiona Harding, PhD||AbbVie Biotherapeutics Inc|
Senior Research Fellow
Fiona Harding trained as an immunologist as the University of Rochester and the University of California, Berkeley. Her specialty is cellular and molecular immunology. Her postdoctoral activities included the characterization of the costimulatory molecule CD28 In Dr James P Allison’s lab. Fiona has over 25 years’ experience in biotechnology and industry, starting her career at GenPharm International (now Medimmune/AstraZeneca) characterizing early humanized mouse models that lead to the generation of the HuMab mouse. She developed and patented an in vitro screening method for the identification of immunogenic T cell epitopes in therapeutic proteins (the iMune Assay) while working at Genencor International (now DuPont). Fiona joined PDL in 2005 and has been working at Abbott/AbbVie since 2010. Fiona has worked on many programs and projects, and is currently leading multiple discovery, pre-clinical, and clinical stage immuno-oncology programs.
|Claire Harris||Newcastle University|
Professor Molecular Immunology, Translational & Clinical Research
Claire’s interest in complement dates back to her undergraduate days when she was inspired by teaching on innate immunity and was intrigued by the ability of a protein-based, soluble system to punch holes in target cells! She obtained her PhD at Cambridge University, UK, and moved to Cardiff, UK, in 1993 as a postdoctoral scientist studying the biochemistry and function of complement proteins in humans and other species. Funding from the Wellcome Trust enabled her to establish a group focused on structure–function relationships in complement activators and regulators with a particular interest in the mechanisms underlying complement dysregulation and disease. Recent work includes functional characterization of complement protein variants/mutants associated with diseases such as age-related macular degeneration (AMD), atypical haemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). This work has led to the concept of the 'complotype' -the influence of complement genetic makeup on inflammation & infection. In 2013, she was appointed as Head of Complement Drug Dicovery at GlaxoSmithKline in the ImmunoInflammation Therapy Area and gained invaluable insight into the process of target and indication validation and drug discovery; she joined Newcastle University in 2016 to further her work in translational research and experimental medicine. With experience both in academia and the pharmaceutical industry, her current research is focussed on therapeutic approaches for modulation or inhibition of the complement cascade, particularly on strategies to target or ‘home’ therapy specifically to disease sites.
|Asa Hatami||Sangamo Therapeutics|
Asa Hatami is currently a scientist at Sangamo Therapeutics, focusing on the use of zinc finger proteins to regulate gene expression as a therapeutic approach for central nervous system disorders. Previously, Asa’s doctoral and postdoctoral training was on the development of small molecules to increase alpha-cleavage of amyloid precursor protein as a therapeutic strategy for the treatment of Alzheimer’s disease; investigation of neuronal exosome-associated molecules as biomarkers of disease state and progression in neurological disorders; investigation of the propagation and toxicity of structurally defined alpha-synuclein fibril polymorphs in vitro and in vivo; as well as the use of preclinical models of Parkinson’s disease, Huntington’s disease, and traumatic brain injury to investigate a broad range of therapeutic strategies for neurodegenerative disorders. Asa holds a PhD from UC Irvine’s Department of Molecular Biology and Biochemistry.
|Torsten Hechler, PhD||Heidelberg Pharma Research GmbH|
Vice President ADC Research, Cell Biology & Biochemistry
Dr. Torsten Hechler is the Vice President ADC Research and as such Head of Biochemistry, Bioanalytics and Cell Biology at Heidelberg Pharma Research GmbH, a pharma company located near Heidelberg (Germany), mainly conducting research and development of anti-cancer drugs. He obtained his diploma degree in biology in 2003 followed by a PhD in microbiology at the Technical University Darmstadt. For his postdoctoral studies at the German Cancer Research Center (DKFZ) in Heidelberg he switched in 2008 the field towards virology. In 2011 he joined the team of Heidelberg Pharma as a group leader and started his work on the development of new ADCs based on the RNA polymerase II inhibitor alpha-Amanitin. He is currently responsible for the ADC Research at Heidelberg Pharma with focus on the development of new Amanitin based ADCs for clinical development.
|Dawn Henke, PhD||Standards Coordinating Body|
Senior Technical Program Manager
Dawn holds a PhD in Genetics and Genomic Sciences from University of Alabama at Birmingham. Prior to joining SCB, she worked as a post-doctoral fellow at the National Institutes of Health in the National Eye Institute performing stem cell research developing retinal organoids for testing and therapeutic purposes from stem cells. Currently she works as the senior technical program manager for the Standards Coordinating Body. Dawn works to oversee all technical projects to coordinate and facilitate the development of standards for regenerative medicine.
|Juan Hernandez Bort||Takeda (Austria)|
Head, Gene Therapy Technologies
Dr Juan A. Hernandez Bort works currently at Takeda (Austria) as Head of Gene Therapy Technologies and he collected, in the past 20 years, extended experience in the upstream and downstream process development of plasma-derived products, recombinants and lately gene therapy products. He hold a Master Degree and PhD in Biotechnology from the University of Natural Resources and Life Sciences in Vienna (BOKU), Austria. His current work is focused on recombinant Adeno-Associated Virus process development for Gene Therapy.
|Kevin Heyries, PhD||AbCellera Biologics Inc|
Co-Founder, Head, Business Development
Kevin Heyries holds a PhD in biochemistry (Uni. of Lyon) where he developed microfluidics for antibody analysis. During his postdoctoral work (Uni. of British Columbia), he developed high throughput microfluidics systems for digital PCR and single-cell genomics. Dr. Heyries was instrumental in the development of AbCellera’s technology, where he is now leading business development and strategy.
|Suzanne Hibbs, MS, MBA||MilliporeSigma|
Senior Product Manager, Cell Design Studio
Suzanne Hibbs earned her BS from Missouri University of Science and Technology, MSc from the University of Missouri, and MBA from Webster University. She has over fourteen years of industrial biotechnology experience that includes ten years of hands-on experience as a Senior R&D Scientist where she genetically engineered cell lines. As a Senior Product Manager, she manages custom cell line engineering product development and oversees the delivery of cellular models to researchers around the world.
|Timothy Hickling, PhD||Pfizer Inc|
Associate Research Fellow, PDM Immunogenicity Sciences
Tim leads the Immunogenicity Sciences group in Pfizer that is responsible for immunogenicity risk assessments, screening biomolecules for improved immunogenicity profiles and developing predictive methods for immune responses. Tim joined Pfizer in the UK in 2007 to develop Vaccines before switching to unwanted immunogenicity, and the USA, in 2011. He had previously obtained his Biochemistry degree and Immunology Doctorate from the University of Oxford, U.K. and was a Lecturer in Virology at the University of Nottingham, U.K.
|Markus Hildinger, PhD||evitria AG|
Dr. Markus Hildinger (CEO, evitria AG) has over 25 years of experience in engineering and production of antibody-based therapeutics. Recognizing the need for fast and cost-effective generation of antibodies, he founded evitria AG in 2010. Today, his company reaches customers around the globe, serving a broad range of clients from academia to global biopharmaceutical companies. Dr. Hildinger has published more than 30 peer-reviewed scientific articles and is co-inventor on numerous patents and patent applications.
|Oliver Hill, PhD||Apogenix AG|
Vice President Molecular Biology
Oliver Hill joined Apogenix in March 2006. He is an expert for protein engineering and expression. Prior to his position at Apogenix, he headed the protein expression and purification group at Graffinity Pharmaceutical Design GmbH (Heidelberg, Germany) from 1999 to 2006. At Graffinity Oliver Hill was responsible for delivering a broad spectrum of target proteins for screening on a chemical microarray platform. His work in former, academic R&D positions at the Lower Saxony Institute for Peptide Research (Hannover, Germany; 1992-1996) and the Institute for Molecular Biotechnology (Jena, Germany; 1997-1998) included gene hunting, protein engineering and the development of recombinant phage display technologies. Mr Hill studied biology at the University of Hannover where he also received his Ph.D. from the Department of Chemistry in 1997.
|Mitchell Ho, PhD||NIH NCI|
Chief Antibody Therapy & Senior Investigator, Molecular Biology Lab
Mitchell Ho is a Senior Investigator in the National Cancer Institute (NCI) and the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH. He received his PhD in the laboratory of Dr. Mariangela Segre at the University of Illinois at Urbana-Champaign, where he used anti-idiotypic antibodies as cocaine antagonists. He completed a postdoctoral fellowship with Dr. Ira Pastan at the NIH, where he engineered immunotoxins targeting CD22 and mesothelin for the treatment of B-cell leukemias and mesothelioma. The Ho laboratory at the NCI studies cancer cell surface proteins, focusing primarily on the role of glypicans including GPC2 and GPC3 as a new family of tumor antigens, and designs 'single domain antibodies' that modulate Wnt and other glypican signaling processes responsible for the development of cancer.
|Soraya Hoelper||Sanofi Aventis Deutschland GmbH|
Lab Head, Mass SpeCenterometry
Dr. Soraya Hölper joined Sanofi in 2017 as a Lab Head for Mass Spectrometry. She is acquainted with developability and analysis of complex therapeutic antibodies within the Biologics Research division. Before joining Sanofi, Soraya was responsible for the establishment and maintenance of the mass spectrometry platform at the Institute of Biochemistry II in Frankfurt am Main. She holds a diploma degree in biochemistry from the Goethe University of Frankfurt am Main and did her Ph.D. at the Max-Planck-Institute for Heart and Lung Research in Bad Nauheim in the Biomolecular Mass Spectrometry division.
|Dietmar Hoffmann, PhD||Sanofi|
Associate Director, Section Head Molecular, Expression and Screening Technologies Group, Biologics Research US
Dietmar Hoffman leads a multidisciplinary team across Sanofi R&D providing project teams with molecular biology support and plasmid storage/management, high-throughput, automated protein/antibody expression, generation of monoclonal antibodies, medium-throughput and combination screens and confocal imaging support. He received his Ph.D. in pharmaceutical biology from the Rheinische Friedrich-Wilhelms University in Bonn, Germany.
|Kristin Hollister||Eli Lilly & Co|
Research Scientist, Experimental Medicine Lab
Kristin Hollister, Ph.D., is a Senior Research Scientist in the Laboratory for Experimental Medicine (LEM) at Eli Lilly and Company, where she functions as an immunogenicity Clinical Advisor. She has worked on numerous clinical development teams from pre-Phase 1 through marketing approval and post-launch activities. She additionally acts as the Communications Leader for LEM and their assay development and validation work. Prior to joining Lilly, Kristin earned her Ph.D. in Microbiology and Immunology, with a focus in follicular helper T cells, from the Indiana University School of Medicine in 2014. Her pervious roles in the company include work in Clinical Pharmacology, Global Patient Health Outcomes, and submission and launch support in the Biomedicines business unit.
|Axel Hoos||GlaxoSmithKline Pharmaceuticals|
SVP R&D Goverance Chair, and Therapeutic Area Head for Oncology
Dr. Axel Hoos is Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). He is responsible for discovery and development in Oncology with focus on immuno-oncology, epigenetics, cell therapies and genetic medicine. As R&D governance chair he oversees technical and funding review committees. He returned GSK to Oncology after the divestment of its marketed medicines to Novartis in 2015 and is responsible for GSK's Oncology portfolio focusing on innovative medicines to deliver transformational benefit to patients. Recent portfolio expansion included the acquisition of Tesaro, a co-development partnership with Merck-Serono, and the in-licensing of the first cell therapy active in solid tumors from Adaptimmune. Dr. Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Director on the Board of Imugene, a biotech company, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). His efforts focus on novel therapies for life-threatening diseases, scientific and technical innovation, and business and scientific collaboration. Through his leadership a paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology (Nat. Rev. Drug Discovery 2016, 15(4):, 235-47). Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy and the first checkpoint inhibitor drug in Immuno-Oncology. The discovery of ipilimumab’s scientific mechanism was honored with the Nobel prize for Physiology or Medicine to Dr. James Allison in 2018. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company. Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.
|Xiaoqing Hua||Merck & Co Inc|
Xiaoqing Hua is a Sr. Scientist in analytical method development group at Merck. Her primary focus is on analytics of therapeutic proteins with LC based separation methods, as well as capillary electrophoresis methods such as icIEF and CE-SDS. Before joining Merck, she did internship in Celgene, biologics downstream and analytical process development group, working on analytical method development, process characterization support, and process development support. She has a PhD in Chemical and Biomolecular Engineering from Johns Hopkins University.
|Peter Hudson||Avipep Pty Ltd|
CSO & Chief Scientist
Dr Peter Hudson, FTSE, BSc Hons (Adelaide, Australia), PhD (MRC-LMB, Cambridge, UK). Peter is CSO of Avipep P/L (Melbourne) and Avipep Therapeutics P/L (Boston) and recently led a large oncology consortium to complete the first Phase 1 clinical trial of a novel engineered antibody (AvibodyTM) targeting prostate and ovarian cancer. Peter has co-founded four Australian biotech companies Evogenix Pty Ltd (2001), Avipep Pty Ltd (2005), CarTherics Pty Ltd (2015) and IsoClide Med Pty Ltd (2017). Peter is currently an Adjunct Professor at the University of Queensland and was formerly a Chief Research Scientist and Program leader in CSIRO (1990-2008) and Deputy CEO and Scientific Director of the CRC for Diagnostics (1995-2007). He was also Director for Business Development in the AIBL Alzheimer’s Disease consortium and the CRC for Mental Health (2009-2012). Peter was elected to the Australian ATSE Academy and has been awarded the AMRAD Biotechnology and CSIRO Chairman’s Medals.
|Shou-Ching Jaminet||Angiex Inc|
Founder & Head of Research
Shou-Ching Jaminet, Ph.D., is Founder and Head of Research at Angiex, Inc. Shou-Ching is a molecular and vascular biologist, a leading expert on gene expression profiling and TM4SF1 biology, and discoverer of TM4SF1’s roles in endothelial cell biology. At Angiex, Shou-Ching has led creation of an antibody-drug conjugate for solid tumors that is in preclinical development. Before founding Angiex, Shou-Ching was Director of the Laboratory of Multi-Gene Transcriptional Profiling at Beth Israel Deaconess Medical Center. She identified TM4SF1 as a new endothelial cell biomarker; elucidated the role of TM4SF1 in blood vessel formation; demonstrated that TM4SF1 is essential for endothelial cell movement and proliferation; discovered a novel internalization route along microtubules to the nucleus; and discovered novel mechanisms of intercellular interaction mediated by TM4SF1-rich nanopodia that may play an important role in metastasis.
|Darshana Jani, MSc||Pfizer Inc|
Associate Director & Global Lead Biologics
Darshana Jani has nearly 25 years of practice in the academic and biotechnology field. Throughout her tenure at Genzyme, Medimmune, BiogenIdec until present employment as Senior Manager at Pfizer she has supported clinical and pre-clinical trials, in addition to post marketing studies inclusive of Safety, Immunogenicity, PK, Efficacy, and Biomarker analysis. Darshana has risen from the ranks, at the outset developing and applying boianalytical methods, while assuming numerous responsibilities germane to regulatory compliance of the validation and application of group procedure. She has guided bioanalytical lab groups, held responsible for overseeing all phases of drug recovery and development; a task which incorporated product characterization, potency determination, immunogenicity testing, as well as surrogate maker discovery.
|Wojciech Jankowski||FDA CBER|
Commissioners Fellow & Biologist, Center for Biologics Evaluation & Research
Dr. Jankowski is a research reviewer with the US Food and Drug Administration in the Office of Tissues and Advanced Therapies. He is part of an active research laboratory and his research interests lie in the regulatory-science associated with the licensure of the next generation of therapeutic proteins. A key focus of his research activities has been to understand the immune response to protein therapeutics, which can significantly affect the efficacy and safety of these drugs. He uses a combination of computational, in vitro and ex vivo approaches in his work. Dr. Jankowski received his Ph.D. from Rutgers University, NJ and was subsequently selected for the highly competitive Commissioner’s Fellowship program at the FDA. His research has been published in high impact journals such as Nature and Nature Chemical Biology.
|Monique Janowski-Egler, PhD||Wacker Biotech GmbH|
Head, USP, BioProcess Development Halle, BioProcess Development
Monique Janowski-Egler, PhD, is Head of Upstream Processing in BioProcess Development at Wacker Biotech. Monique is trained as molecular biologist and microbiologist. Within more than 10 years she developed significant experience in E. coli strain and fermentation development of small and large scale production processes for various biopharmaceuticals.
|Martin Jarrold||Indiana University|
Martin F Jarrold obtained his undergraduate and graduate degrees from the University of Warwick in England, and then went to the University of California, Santa Barbara as a NATO Postdoctoral Fellow. After several years in California, he joined the Physics Research Division of AT&T Bell Laboratories in Murray Hill, New Jersey. In 1992, he moved to Northwestern University to become a Professor in the Chemistry Department. While at Northwestern he performed pioneering work on ion mobility mass spectrometry. In 2002 he moved to Indiana University as Professor and Robert and Marjorie Mann Chair. His recent work at IU has focused on developing charge detection mass spectrometry.
|Vibha Jawa, PhD||Merck & Co Inc|
Director, Predictive & Clinical Immunogenicity
Dr. Vibha Jawa obtained her Ph.D. in Biochemistry and Immunology with a thesis work studying the immune mechanisms behind autoimmune diseases. This was followed by a postdoctoral fellowship at University of Pennsylvania where she did extensive work on assay development for monitoring the immune response to viral vectors. She then moved to the Bay area where she worked with a gene therapy company evaluating viral vectors for hemophilia therapy. Subsequently, she moved to Southern California where she worked for City of Hope Cancer Centre Stem Cell and Gene Therapy group prior to moving to Amgen in 2003. Until recently she was a Principal Investigator and Clinical Immunology representative on several of Amgen’s drug development teams where she provided input to develop appropriate immunogenicity risk assessment strategies. Her current research interests include evaluating immune response biomarkers for early drug development and efficacy, immunogenicity prediction using in silico, in vitro and in vivo technologies, modeling impact of immunogenicity on PK and PD, antigen processing and presentation and the role of T cells in immune response to drug products.
|Hao Jiang||Bristol Myers Squibb Co|
Senior Research Investigator II
Hao is currently a Principal Scientist at Bristol-Myers Squibb, who has worked at BMS for 13 year after 4-years postdoc training at University of Pennsylvania School of Medicine. He is working as a bioanalytical project lead outsourcing both small molecule and biologics projects in multiple disease areas. Hao has also taken the role as a technical lead for in-house assay development in several bioanalytical areas such as protein bioanalysis by LC-MS and PK/ADA bioanalysis on different assay platforms. He has presented his research work in many scientific conferences and published about 50 peer-reviewed papers. He is now the active members of several academic societies such as AAPS and ASMS.
|Wim Jiskoot, PhD||Leiden University|
Professor, Drug Delivery Technology
Wim Jiskoot is professor at the Division of BioTherapeutics at Leiden University (since 2006), the Netherlands, and scientific advisor at Coriolis Pharma, Martinsried, Germany (since 2013). His main research area is biologics formulation. He coedited 3 books about protein characterization and (co)authored over 300 scientific papers and book chapters.
|Karin Jooss||Gritstone Oncology Inc|
Karin Jooss, Ph.D. has served as our Executive Vice President of Research and Chief Scientific Officer since April 2016. Prior to Gritstone, from May 2009 to April 2016, Dr. Jooss served as head of cancer immuno-therapeutics in the vaccine immuno-therapeutics department at Pfizer, Inc., or Pfizer, a public pharmaceutical company, where she was also a member of the vaccine immuno-therapeutics leadership team and served as head of the immuno-pharmacology team. Prior to joining Pfizer, Dr. Jooss served as vice president of research at Cell Genesys, Inc., or Cell Genesys, from June 2005 to April 2009, and as senior director of research at Cell Genesys from July 2001 to June 2005. She is on the editorial board of Molecular Therapy and the Journal of Gene Medicine and is a member of the Immunology and Educational Committee of the American Society of Gene & Cell Therapy and the Industry Task Force of the Society for Immunotherapy of Cancer. Dr. Jooss received her diploma in theoretical medicine from the University of Marburg in Germany, a Ph.D. in molecular biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania.
|Teemu Junttila, PhD||Genentech Inc|
Dr. Junttila joined Genentech in 2006. Currently his research is focused in developing Genentech’s T cell dependent bispecific (TDB) antibodies and he is responsible of multiple CD3-bispecific molecules in various stages, ranging from early stage research to clinical development.
|Tina Kang||GenScript ProBio|
Senior Scientist, Discovery
Dr. Manzhu Kang received her Ph. D. from the University of California Los Angeles, with a dissertation focusing on the impact of combinatorial therapy on the evolution of drug resistance. Dr. Kang is a senior scientist of antibody research group at GenScript ProBio. She is in charge of the single B cell screening platform for antibody drug discovery.
|Dennis Karthaus, MSc||IBA Lifesciences|
Director Protein Products & Assays
Dennis Karthaus received his master`s degree in biotechnology from the Univ. of Applied Sciences in Bremerhaven. During his thesis he worked on the development of protein purification platforms and in cell line development. In 2012, Dennis Karthaus joined IBA Lifesciences. He's leading the department for protein purification & assays and is responsible for the development of products & technologies for protein expression, purification and analysis.
|Kawaljit Kaur||University of Kansas Lawrence|
Associate Researcher, Vaccine Analytics & Formulation Center VAFC
Kawaljit Kaur is an associate researcher at the Vaccine Analytics and Formulation Center in the Department of Pharmaceutical Chemistry at the University of Kansas. Dr. Kaur received her undergraduate degree in Biophysics at Panjab University, India, and PhD in Biochemistry and Biophysics from University of Kansas in 2016. Her PhD research utilized protein Nuclear Magnetic Resonance (NMR) spectroscopy as a major biophysical tool to characterize protein-protein interactions that play important role in bacterial pathogenesis. Her current research projects involve using state-of-the-art mass spectrometry and other biophysical techniques, such as, calorimetry, fluorescence, and biolayer interferometry, to characterize and compare the physicochemical properties of various vaccine antigens.
|John Kelly||Natl Research Council Canada|
Senior Research Officer
John received a B.Sc. in Chemistry and Biochemistry from the National University of Ireland (Galway). He worked for a number of years as a product development chemist in Elan Pharmaceuticals before deciding to pursue higher academic studies in Canada. John holds a Ph.D in Analytical Chemistry from Dalhousie University. He was an NSERC industrial postdoctoral fellow at Merck Frosst in Montreal before joining the National Research Council of Canada (NRC) in 1997 as a Research Associate. John is now a Senior Research Officer at NRC’s Human Health Therapeutics (HHT) Research Centre in Ottawa, Ontario. His research focuses primarily on the mass spectrometry analysis of proteins in support of HHT’s biotherapeutics and vaccine development initiatives.
|Saad Sirop Kenderian||Mayo Clinic|
Assistant Professor of Medicine & Oncology & Senior Consultant
Dr. Kenderian is a physician scientist in the departments of Hematology, Immunology and Molecular Medicine at the Mayo Clinic in Rochester, MN. He is Assistant Professor of Medicine, Oncology and Immunology and he directs the T Cell Engineering Laboratory Program. He work is focused on the development of novel chimeric antigen receptor strategies to enhance their safety, efficacy and application of CART cell therapy and to develop next generation therapeutics. He is an author of over 50 scientific papers and several book chapters. He is an inventor on multiple patents in this field
|Bruce Keyt, PhD||IGM Biosciences Inc|
Bruce received his Ph.D. in biochemistry and pharmacology from Tufts University School of Medicine and his B.S. in Chemistry from Washington University in St Louis. He is a co-inventor on more than 35 U.S. patents and patent applications, and he has a co-authored more than 55 scientific articles. Bruce brings to IGM more than thirty-five years of research, development and management experience in large and small biotechnology companies, including his extensive experience in many phases of early stage drug discovery and development. This experience spans target selection and discovery, in vitro biochemistry, in vivo efficacy models and all other aspects of the pre-clinical development of antibodies and proteins as therapeutic agents.
|Maura Kibbey, PhD||USP|
Senior Scientific Fellow, Education & Training, Global Biologics
Dr. Maura Kibbey is a Senior Scientific Fellow for Education and Training in USP’s Global Biologics Department. Dr. Kibbey leads development of courses, workshops, and forums to engage USP’s biologics stakeholders. This role builds on her previous responsibilities directing USP scientists developing compendial standards. Before joining USP, Dr. Kibbey worked for several biotechnology and diagnostic companies in the Washington DC area in scientific, management, marketing, and business development roles, as well as performing cancer research at the National Institutes of Health. She has published over 40 peer-reviewed articles and has been an invited speaker or workshop organizer for numerous scientific conferences.
|Philip Kim||University of Toronto|
Associate Professor, Molecular Genetics & Computer Science
Philip M. Kim is a Professor at Donnelly Centre at the University of Toronto. He leads a research laboratory that integrates machine learning, physics-based modeling and wet/experimental methods for engineering of biologics. He is a Co-founder of Resolute Bio, a drug development startup company. He authored over 70 publications, 7 invention disclosures and 3 patent applications. Before to setting up his lab in 2009, he was a postdoctoral fellow at Yale University where he pioneered structural analyses of protein interactions networks and an associate with McKinsey & Co. He holds a Ph.D. from the Artificial Intelligence Laboratory and Department of Chemistry at the Massachusetts Institute of Technology and a B.S. in Biochemistry and Physics from the University of Tuebingen.
|Seokjoong Kim||ToolGen Inc|
Executive Director, R&D Strategy and Strategic Alliances
Seokjoong Kim is an experienced molecular biologist in the field of programmable nuclease development and genome editing technology. Currently, Seokjoong is leading research and business development of ToolGen, Inc., Korean biotech focused on the translation of CRISPR/Cas9 technology into valuable products in the field of therapeutics. Following his Ph.D. studies in Molecular Medicine at University of Texas Health Science Center at San Antonio, Seokjoong joined the group of Prof. Jin-Soo Kim at Seoul National University as a postdoctoral researcher where he started a career in genome editing with the development of zinc finger nucleases and TAL effector nucleases.
|Sunnie Kim||Seattle Genetics Inc|
Senior Scientist, Analytical Sciences
Sunnie Kim is a Senior Scientist in Analytical Sciences group in Process Development at Seattle Genetics. Prior to this, she worked at CMC Biologics and Bio Process Development in Merck, Kenilworth NJ. Sunnie Kim received her Ph.D. in Analytical Chemistry at Indiana University under the guidance of Professor David Clemmer. She then completed her NIH postdoctoral fellowship at The Rockefeller University in NY working with Professor Brian Chait on Biological Mass Spectrometry.
|Chava Kimchi-Sarfaty, PhD||FDA CBER|
Acting Deputy Associate Director Research, Plasma Protein Therapeutics
Chava Kimchi-Sarfaty currently leads a group at the FDA within the Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies (OTAT) that investigates various blood coagulation factors with a specific focus on the genetic determinants of coagulation factor biosynthesis and structure. She is also the Acting Deputy Associate Director for Research of the Office. She reviews and chairs pre-INDs, INDs and BLAs for recombinant proteins and plasma derivatives products such as von Willebrand factor, ADAMTS13, factor VIII, FIX, thrombin and fibrinogen.
|Priya Kishnani||Duke University|
Professor, Pediatric Medical Genetics
Dr. Priya Kishnani is Chief, in the division of Medical Genetics at Duke University Medical Center as well as Director of the YT and Alice Chen Pediatrics Genetics and Genomics Center. Dr. Kishnani moved to the United States in 1991, after completing a residency in Pediatrics in Mumbai, India. She went on to do a second residency in Pediatrics as well as a Fellowship in Genetics and Metabolism at Duke University Medical Center. Shortly after, she joined the faculty at Duke University and has worked as a Professor of Pediatrics in the Pediatrics and Medical Genetics departments. Dr. Kishnani is certified by the American Board of Medical Genetics and the American Board of Biochemical Genetics. She also serves as the Director of the Lysosomal Storage Disease Program, Biochemical Genetics Training Program, and Metabolic Clinic at DUMC.
|Christian Klein, PhD||Roche Pharma Research & Early Development|
Head, Oncology Programs & Depart Head Cancer Immunotherapy Discovery 3, Roche Innovation Center Zurich
Dr. Christian Klein is currently Head of Oncology Programs and Department Head Cancer Immunotherapy Discovery 3 at the Roche Innovation Center Zurich. He joined Pharma Research at the Roche Innovation Center Munich in Penzberg in 2002 as a postdoctoral fellow. After the acquisition of Glycart Biotechnology AG by Roche, he became the preclinical science leader for obinutuzumab and then joined the Roche Innovation Center Zurich as Head of Oncology Programs before taking on his current role in 2015. Christian Klein holds a diploma in biochemistry from the University of Tübingen and did his PhD at the Technical University Munich and completed his habilitation in Biochemistry at the Ludwig-Maximilians University in Munich. He is a co-author on >120 peer-reviewed publications and reviews, co-editor of the book series „Successful Drug Discovery“, an editorial board member of “mAbs“ and “Antibodies“ and named as a co-inventor on >150 patent applications in the fields of cancer research, therapeutic/bispecific antibodies and antibody engineering. During his 17 years at Roche, Christian has made major contributions as a research project leader to the preclinical development and approval of GAZYVA/GAZYVARO, to the preclinical development of twelve bispecific antibodies, immunocytokines and antibody fusion proteins entering clinical trials and lead research on preclinical antibody-based cancer immunotherapy projects and combination therapy.
|Hans Klingemann||NantKwest Inc|
Vice President R&D
Dr. Klingemann is currently VP of Research and Development at NantKwest (NASDAQ: NK), the company he founded in 2002 as ZelleRx based on the core technology of NK-92. He is the former Director of the Bone Marrow and Stem Cell Transplant Program at Boston’s Tufts Medical Center and the Cancer Center’s Hematological Malignancies Program. Before coming to Boston, Dr. Klingemann served as Director of Bone Marrow Transplant and Cell Therapy at Rush University Medical Center in Chicago, and was the founding Director of the Sramek Center for Cell Engineering. He has worked as physician, scientist, educator, and administrator in leadership positions for more than 25 years at various academic medical centers in Europe, Canada and the United States and has authored over 170 scientific and medical papers. He maintains a professorship at Tufts Medical Center.
|James Koerber, PhD||Genentech Inc|
Scientist, Antibody Engineering
JT received his PhD in Chemical Engineering from the University of California Berkeley where he developed novel protein engineering strategies for viral gene therapy. He then completed a post-doc with Jim Wells at the University of California San Francisco where he developed a novel structure-based design platform to generate phospho-specific antibodies. At Genentech, he works in the collaborative environment to discover novel biology and transformative drugs. Our goal is to advance new therapies to patients by tackling challenging targets and engineering around drug delivery barriers.
|M. Eric Kohler, MD, PhD||Children's Hospital Colorado|
Instructor, Blood and Marrow Transplant and Cellular Therapeutics, Center for Cancer and Blood Disorders
No bio available
|Shohei Koide||New York University|
Professor & Principal Investigator, Biochemistry & Molecular Pharmacology
Shohei Koide, Ph.D. is a synthetic protein scientist. His research integrates structure-guided design and directed evolution to design highly functional but still simple proteins. He is the inventor of the Monobody technology, and he has made important contribution to the development of synthetic antibody technologies. His current research focuses on the discovery of cancer therapeutics and on establishing strategies to control "undruggable" targets. Previously he was Professor at University of Chicago and at University of Rochester School of Medicine and Dentistry.
|Leopold Kong||FDA CDER|
Dr. Kong has been a biologics quality and immunogenicity reviewer with the Office of Biotechnology Products, Center for Drugs- FDA since 2017. He received his PhD on Structure-Based Vaccinology in 2010 from the University of Oxford, Oxford, England, UK. Since joining the FDA, Dr. Kong has accrued regulatory experience in reviewing innovator biologics and serves as an active member of the Immunogenicity Working Group in the Office of Biotechnology Products.
|Helen Kotanides||Eli Lilly & Co|
Senior Research Advisor
No bio available
|Aleksandr Kovaltsuk, MSc (Glas.)||University of Oxford|
DPhil Student, Oxford Protein Informatics Group, Department of Statistics
Aleksandr Kovaltsuk received his MSc degree in Pharmacology from the University of Glasgow in 2016, conducting his research year in the Antibody Discovery and Protein Engineering department at MedImmune (AstraZeneca) in Cambridge, UK. He then joined the Oxford Protein Informatics Group at the University of Oxford to study for a DPhil under the supervision of Professor Charlotte Deane in collaboration with UCB Pharma. In 2017 he was awarded a Royal Commission Industrial Fellowship. He authored the Observed Antibody Space (OAS) antibody next-generation sequencing [Ig-seq] database, and the ABOSS and SAAB+ tools for error-filtering and structurally annotating Ig-seq datasets respectively. He has written a review on the benefits of structural Ig-seq analysis. His current project involves developing software for immunodiagnostics and humanisation.
Head, Bioassay Department
PhD. Head of Bioassay Department at Biocad, Russian Leading Innovative Biotechnology Company. The department is responsible for selection the bioassay strategies and development, validation and transfer bioassays including potency assays in support of drug development pipeline.
|Serguei Kozlov, PhD||Frederick National Laboratory for Cancer Research (NCI)|
Principal Scientist/PM, Team Leader Preclinical Technology and Optimization Team, Center for Advanced Preclinical Research
Internationally recognized expert in advanced methodologies for developing genetically and biologically engineered preclinical murine disease models for studies of the molecular mechanisms of carcinogenesis, tumor immune response, immune surveillance, and inflammation, mechanisms of drug resistance, implication of cancer stem cells, etc.; and to explore such models for preclinical drug development, disease systems analyses and biomarker discovery. Initiated, supervised, and successfully conducted multiple research projects and independent large-scale research and development programs aimed at investigation of molecular mechanisms governing carcinogenesis, biomarker discovery and preclinical drug evaluation in various mouse models. Oversees the preclinical technology development operations at the Frederick National Laboratory Center for Advanced Preclinical Research – an innovative preclinical cancer modeling and drug development initiative based on genetically engineered murine models – with senior management responsibilities. Co-authored over 70 scientific papers, book chapters and original works in peer-reviewed journals.
|Dennis Krieg||Ludwig Maximilians University|
Graduate Student, Pharmacy
Dennis Krieg is a pharmacist by training and Ph.D. student in the research group of Prof. Dr. Gerhard Winter at the Ludwig-Maximilians-University Munich, Germany. In his thesis, Dennis focuses on different aspects of protein co-formulations. His work includes the analytical characterization, formulation development, stability testing and interaction studies of co-formulations for therapeutically relevant cytokines, enzymes and antibodies.
|Andrew Kruse, PhD||Harvard Medical School|
Assistant Professor, Biological Chemistry & Molecular Pharmacology
Andrew Kruse an Associate Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Prior to joining the faculty at Harvard, he completed doctoral training with Brian Kobilka at Stanford University where he studied neurotransmitter receptor structure and pharmacology. Research in the Kruse lab focuses on structure and mechanisms of transmembrane signaling proteins, with a particular emphasis on the development and application of antibody fragments as tools to study signaling receptors. Dr. Kruse is the recipient of a Smith Family Award for Excellence in Biomedical Research, a Klingenstein-Simons Fellowship, a Vallee scholar award, and an NIH Director’s Early Independence Award.
|Amit Kumar||AstraZeneca Biologics|
Scientist I, ADPE
Amit Kumar received his PhD in Chemistry from the University of Houston. He then pursued postdoctoral work at University of Texas southwestern Medical Center where he worked on design and synthesis of molecular imaging probes and therapeutic agents for various diseases. He joined AstraZeneca in 2016 and is currently working on antibody-drug conjugates and novel conjugation modalities for oncology applications.
|Prashant Kumar||University of Kansas Lawrence|
Senior Scientist, Pharmaceutical Chemistry
Prashant Kumar is a Senior Scientist at Vaccine Analytics and Formulation Center (VAFC) at the University of Kansas, Lawrence. He received his Ph.D. in Bioprocess Technology in 2015 from the Institute of Chemical Technology, India. He then joined the University of Kansas for his postdoctoral research on multi-subunit vaccines. Prashant’s current research focuses on development of stable, low-cost, vaccine formulations including rotavirus, poliovirus, HPV and combination vaccines. His research involves application of high throughput analytical methods, process integration, continuous processing and Design of Experiments (DOE) for process optimization and cost minimization of the vaccine drug products. Prashant has several publications to his credit and is serving as reviewer for various scientific journals. He is committed to high standards of research, cross-functional teamwork, relationship building and scientific collaboration across multiple disciplines.
|Seema Kumar, PhD||EMD Serono R&D|
Associate Director Drug Metabolism & Pharmacokinetics
Seema Kumar is currently an Associate Director and a DMPK senior project representative at EMD Serono Inc. (a business of Merck KGaA, Germany). In her role, Dr. Kumar is responsible for overall NBE drug disposition support including DMPK/ADME, Bioanalysis (BA) and Immunogenicity strategy for biotherapeutics from the concept generation through discovery and development stages. Previously, Dr. Kumar led regulated Bioanalytical group in BioMedicine Design (formerly PDM-NBE) department at Pfizer. The group provided regulated (GLP/GCP) BA support including assay development, validation and sample analysis for PK, ADA and Nab assessments for pre-clinical and clinical development of Pfizer’s large molecule portfolio. Dr. Kumar also managed Core Automation Team (CAT) engaged in automated large-molecule bioanalysis using Hamilton robotic liquid handlers. Prior to joining Pfizer, Dr. Kumar had served at roles of increasing responsibility as Director of Quality Control and Director of CLIA certified Clinical Bioanalytical Lab at XBiotech USA Inc. Dr. Kumar holds a PhD in Biophysical Chemistry from Johns Hopkins University and has published several publications in peer-reviewed journals and contributed to several book chapters. Dr. Kumar has also given numerous talks in various national and international scientific conferences and meetings. Dr. Kumar has a special interest in Pharmacokinetics and Drug Disposition of multidomain biotherapeutics.
|Joshua LaBaer, MD, PhD||Arizona State University|
Executive Director & Professor, Molecular Sciences
Joshua LaBaer is one of the nation’s foremost investigators in the rapidly expanding field of personalized diagnostics. His efforts focus on the discovery and validation of biomarkers — unique molecular fingerprints of disease — which can provide early warning for those at risk of major illnesses, including cancer and diabetes. Formerly founder and director of the Harvard Institute of Proteomics, LaBaer was recruited to ASU’s Biodesign Institute as the first Piper Chair in Personalized Medicine in 2009. The Virginia G. Piper Center for Personalized Diagnostics (VGPCPD) has a highly multidisciplinary staff of molecular biologists, cell biologists, biochemists, software engineers, database specialists, bioinformaticists, biostatisticians, and automation engineers. VGPCPD applies open reading frame clones to the high throughput (HT) study of protein function. In addition, his group invented a novel protein microarray technology, Nucleic Acid Programmable Protein Array, which has been used widely for biomedical research, including the recent discovery of a panel of 28 autoantibody biomarkers that may aid the early diagnosis of breast cancer. LaBaer earned his medical degree and a doctorate in biochemistry and biophysics, from the University of California, San Francisco. He completed his medical residency at the Brigham and Women’s Hospital and a clinical fellowship in oncology at the Dana-Farber Cancer Institute, both in Boston. He has contributed more than 150 original research publications, reviews and chapters. LaBaer is an associate editor of the Journal of Proteome Research, a recent member of the National Cancer Institute’s Board of Scientific Advisors, Chair of the Early Detection Research Network Steering Committee and recent president of the U.S. Human Proteome Organization.
|John LaCava, PhD||European Research Institute for the Biology of Ageing|
Group Leader, Lab of Macromolecules & Interactomes
Dr. John LaCava is an NIH-funded investigator, Research Faculty member at The Rockefeller University, and a Group Leader at the European Research Institute for the Biology of Ageing. He focusses on the development of affinity proteomic methods to capture and characterize endogenous macromolecules – lately pursuing molecular pathophysiology and associated perturbations in protein interaction networks.
|Simon Lacey||Hospital of the University of Pennsylvania|
Director, Center for Cellular Immunotherapies, Translational & Correlative Studies Lab
In 1998 Dr. Lacey moved to the Beckman Institute of the City of Hope, where, as an Associate Research Professor and Principal Investigator in Don Diamond’s Laboratory of Translational Vaccine Research, he studied viral and tumor immunity. During this period he was the recipient of investigator awards from the Leukemia and Lymphoma Society, NIAID and NIDDK. In 2010, he assumed the Directorship of the Clinical Immunobiology Studies Laboratory at the Beckman Institute. In 2012 he moved to the University of Pennsylvania, where he is currently Director of the Translational and Correlative Studies Laboratory. The TCSL supports numerous Phase I and II trials of engineered cellular therapies for cancer, infectious and autoimmune disease by performing molecular, cellular and biochemical assays on manufactured cellular products and on patient samples.
|Alden Ladd||bluebird bio|
Senior Associate Scientist, Cellular Therapy Mfg & Process Development
Alden Ladd is a scientist II at bluebird bio (Cambridge MA) where he has been employed for six years. During his time at bluebird he has participated in the process development and technology transfer of all of bluebird’s internal oncology programs. Alden is a subject matter expert in cellular process development and scale up, and is currently leading the technology transfer of bluebird bio’s first TCR based therapy for MAGE-A4 positive solid tumors. Alden is also leading in vivo efforts to understand surrogate biomarkers of potency for CAR and TCR based products. Alden holds a degree in biochemistry from Northeastern University.
|Arthur Laganowsky, PhD||Texas A&M University|
Assistant Professor, Chemistry
My doctoral work focused on structural studies of amyloid-related proteins using X-ray crystallography that received the biochemistry distinguished dissertation award. In my doctoral research, I used pioneering micro X-ray crystallography along with a combination of techniques including the modification, design, expression, and purification of proteins/peptides, as well as structural and computational modeling. As a Nicholas Kurti Junior Research Fellow of Brasenose College in the laboratory of Professor Dame Carol V. Robinson at the University of Oxford, I pioneered novel ion mobility mass spectrometry approaches and methods to study membrane proteins and their interactions with lipid/drug molecules. Since starting my own group in 2014, we have continued to pioneer native mass spectrometry approaches to determine lipid binding thermodynamics and cooperativity, allostery within protein-protein, protein-lipid interactions, and heterogenous lipid binding events to membrane proteins.
|Ching-Ha Vicky Lai||Regeneron Pharmaceuticals Inc|
Senior Staff Scientist, Bioanalytical Pharmaceuticals
No bio available
|Jonathan Lai, PhD||Albert Einstein College of Medicine|
Associate Professor, Biochemistry
Jonathan Lai is Professor of Biochemistry at the Albert Einstein College of Medicine in the Bronx, NY. Dr. Lai received his undergraduate training in Biochemistry at Queen’s University in Kingston, Ontario, Canada, then obtained his PhD in Chemistry and Biophysics at the University of Wisconsin, Madison in 2004. From 2004-2007, he was Helen Hay Whitney Post-Doctoral Fellow in Biological Chemistry at Harvard Medical School. He began his independent lab at the Albert Einstein College of Medicine in 2007. His group has broad interests in peptide, protein, and antibody engineering with application of these methods to discovery of new immunotherapies and vaccines.
|Lawrence Lamb Jr||Incysus Therapeutics Inc|
Executive Vice President & CSO
Dr. Lamb was first to describe the association between relapse-free survival and gdT cell recovery in bone marrow transplant patients. For 26 years, most recently as Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham, Dr. Lamb developed the scientific support for gdT cell-based immunotherapies. Today, this work has brought us to the first clinical trials for allogeneic gdT cell therapy in leukemia patients undergoing haploidentical stem cell transplants and the first gene-modified gdT cell therapy for glioblastoma. Dr. Lamb currently directs clinical and translational research strategy and operations for Incysus Therapeutics.
|John Lambert||Independent Consultant|
Dr. Lambert graduated from Christ’s College, University of Cambridge (England, UK), with a degree in Natural Sciences in 1972. He then went on to earn a Ph.D. in Biochemistry (1976) from the University of Cambridge, working on enzyme structures under the supervision of Professor Richard N. Perham. Dr Lambert’s postdoctoral training was at the University of California, Davis, working on ribosome structure in the laboratory of Dr Robert R. Traut (1976-1980), and at the University of Glasgow, Scotland working on the arom multienzyme complex in the laboratory of Dr John R. Coggins (1980-1982). In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics. Dr. Lambert joined ImmunoGen in 1987 when the company established independent research laboratories in Cambridge, Massachusetts. After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016, followed by a year (2017) on the Executive Committee in an Emeritus capacity. During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla® (approved in 2013 for treating HER2+ breast cancer), as well as numerous other ADCs taken into clinical development. One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in a phase 3 trial for the treatment of platinum-resistant ovarian cancer. Dr Lambert is the author/co-author of over 120 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). In 2018, he was appointed as an Honorary Professor of Queen’s University, Belfast, Northern Ireland, UK.
|David Lansky, PhD||Precision Bioassay, Inc|
David Lansky has been learning about and statistics for bioassays (and other non-clinical applications in Pharma) for over 30 years. His training includes a year of Electrical and Computer Engineering (University of Michigan), a BS in Botany (San Francisco State), an MS in Entomology (Cornell) and finally both an MS and Ph.D. in Biometry (both Cornell). His work experience includes 10 years at Searle/Monsanto/Pharmacia and 17 years as the owner of Precision Bioassay, Inc. David is part of the team revising the USP bioassay chapters.
|Steven Larson||Memorial Sloan Kettering Cancer Center|
Head, Larson Lab
Steven M. Larson, MD., FACNM, FACR is currently the Donna and Benjamin M. Rosen Chair; Attending, Molecular Imaging and Therapy Service, Department of Radiology; Co-Leader, Imaging and Radiation Sciences, Member, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center. Dr. Larson’s primary expertise is in radiolabeled drug development and radiopharmacology of diagnostic imaging and therapy in oncology using small molecules and monoclonal antibodies. Dual-boarded in nuclear medicine and internal medicine, his clinical skills center on oncology, cancer immunology, and clinical thyroid cancer. Dr. Larson has extensive experience as an advisor to public and private institutions, having served, among other appointments, as a member of what is now the MEDI grant review committee of NIH, the DOE Office of Science Advisory Committee, and the American Board of Nuclear Medicine, and as Chair of the Radiopharmaceutical Advisory Committee of the USFDA, Co-Chair of the National Research Council of the NAS Committee on Molybdenum-99 production with non-enriched Uranium 235, Chair of the Molecular Imaging Committee of RSNA, and Co-Chair of the Clinical Imaging Steering Committee of the NCI, and Chair of the NIH Clinical “Impact” Study Section, as well as a member of the Academy of Medicine. Dr. Larson has received numerous awards for excellence in nuclear medicine, including the Hevesy Award, Cassen Prize, Wiley Prize (US FDA), and the Saul Hertz Award of the Society of Nuclear Medicine USA. He is a member of the National Academy of Medicine of the National Academies of Science, USA.